id
stringlengths
22
37
tokens
sequence
ner_tags
sequence
texts
stringlengths
0
39.2k
1266026-04-Results-p01
[ "Ages", "at", "cancer", "can", "be", "used", "to", "estimate", "likely", "numbers", "of", "oncogenic", "mutations", "required", "before", "transformation", "[3-6,11].", "Average", "ages", "for", "sporadic", "MSI+,", "MSI-,", "and", "HNPCC", "cancers", "were", "respectively", "71.5,", "67.5,", "and", "50.3", "years", "(Figure", "1A).", "For", "HNPCC", "cancers,", "estimated", "numbers", "of", "oncogenic", "mutations", "were", "between", "four", "and", "seven", "(95%", "credibility", "interval),", "with", "the", "most", "likely", "value", "of", "five", "mutations", "(Table", "1).", "For", "MSI+", "sporadic", "cancers,", "estimated", "numbers", "of", "mutations", "were", "between", "six", "and", "nine", "(95%", "credibility", "interval)", "with", "more", "likely", "values", "of", "seven", "or", "eight", "mutations.", "The", "most", "likely", "number", "of", "mutations", "was", "seven", "for", "sporadic", "MSI-", "cancers." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Ages at cancer can be used to estimate likely numbers of oncogenic mutations required before transformation [3-6,11]. Average ages for sporadic MSI+, MSI-, and HNPCC cancers were respectively 71.5, 67.5, and 50.3 years (Figure 1A). For HNPCC cancers, estimated numbers of oncogenic mutations were between four and seven (95% credibility interval), with the most likely value of five mutations (Table 1). For MSI+ sporadic cancers, estimated numbers of mutations were between six and nine (95% credibility interval) with more likely values of seven or eight mutations. The most likely number of mutations was seven for sporadic MSI- cancers.
1601966-06-Methods-p01
[ "BIO+cRNAs", "were", "hybridized", "on", "Affymetrix", "Human", "Genome", "U133A", "and", "U133B", "GeneChips,", "that", "consist", "of", "44.928", "probe", "sets", "(Affymetrix,", "Santa", "Clara,", "CA).", "Fragmentation,", "preparation", "of", "hybridization", "cocktails,", "hybridization,", "washing,", "staining", "and", "scanning", "of", "Affymetrix", "GeneChip", "were", "performed", "according", "to", "the", "manufacturer's", "protocols." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
BIO+cRNAs were hybridized on Affymetrix Human Genome U133A and U133B GeneChips, that consist of 44.928 probe sets (Affymetrix, Santa Clara, CA). Fragmentation, preparation of hybridization cocktails, hybridization, washing, staining and scanning of Affymetrix GeneChip were performed according to the manufacturer's protocols.
1601966-03-Results-p08
[ "The", "region", "4p15.31-4p15.2", "is", "part", "of", "a", "larger", "region", "(see", "Table", "1)", "that", "showed", "marked", "down-regulation", "of", "expression", "in", "our", "tumor", "samples", "(see", "Figures", "21,", "22,", "23).", "Full", "or", "partial", "losses", "of", "chromosome", "4", "are", "well", "known", "phenomena", "in", "the", "development", "of", "CRC", "[18,19,23,24].", "One", "of", "the", "strongly", "down-regulated", "genes", "in", "this", "region", "is", "the", "SLIT2", "gene", "at", "4p15.31", "that", "encodes", "a", "membrane", "protein", "regulating", "cellular", "migration.", "It", "has", "recently", "been", "described", "as", "a", "new", "tumor", "suppressor", "gene", "in", "CRC,", "gliomas,", "lung", "and", "breast", "tumors", "and", "seems", "to", "be", "transcriptionally", "inactivated", "by", "epigenetic", "silencing", "[31-33].", "In", "addition,", "several", "other", "genes", "of", "this", "region", "could", "serve", "as", "candidate", "class", "II", "tumor", "patient", " ", "subgroups.", "View", "this", "plot", "in", "conjunction", "with", "Figures", "9", "and", "11." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The region 4p15.31-4p15.2 is part of a larger region (see Table 1) that showed marked down-regulation of expression in our tumor samples (see Figures 21, 22, 23). Full or partial losses of chromosome 4 are well known phenomena in the development of CRC [18,19,23,24]. One of the strongly down-regulated genes in this region is the SLIT2 gene at 4p15.31 that encodes a membrane protein regulating cellular migration. It has recently been described as a new tumor suppressor gene in CRC, gliomas, lung and breast tumors and seems to be transcriptionally inactivated by epigenetic silencing [31-33]. In addition, several other genes of this region could serve as candidate class II tumor patient subgroups. View this plot in conjunction with Figures 9 and 11.
2386495-05-Discussion-p04
[ "The", "61", "different", "APC", "mutations", "listed", "in", "Additional", "file", "2", "were", "identified", "among", "81", "of", "the", "96", "families", "of", "the", "Swedish", "Polyposis", "Registry", "that", "were", "screened", "for", "APC", "mutations.", "Fifteen", "of", "the", "cases", "shown", "to", "be", "APC-mutation", "negative", "where", "all", "subjected", "to", "mutational", "screening", "of", "the", "MUTYH", "gene", "and", "six", "of", "them", "were", "shown", "to", "carry", "biallelic", "MUTYH", "mutations", "(reported", "in", "Kanter", "Smoler", "et", "al[31]).", "The", "overall", "mutation-detection", "rate", "in", "APC", "and", "MUTYH", "among", "the", "families", "in", "our", "study", "was", "thus", "90%.", "In", "total,", "84%", "of", "the", "families", "carried", "APC", "mutations", "while", "6%", "where", "positive", "for", "biallelic", "MUTYH", "mutations.", "The", "mutation-detection", "rate", "we", "have", "reached", "in", "this", "study", "is", "notably", "high.", "In", "fact,", "a", "disease-causing", "mutation", "was", "detected", "in", "all", "cases", "who", "presented", "with", "a", "classical", "FAP", "phenotype", "(except", "for", "family", "1", "(C152),", "where", "we", "have", "clear", "indications", "for", "inactivation", "of", "the", "APC", "transcription).", "The", "mutation-negative", "patients", "all", "display", "an", "attenuated", "form", "of", "disease.", "However,", "as", "we", "have", "also", "found", "subtle", "mutations", "in", "the", "APC", "gene", "in", "patients", "mutation-negative", "patients", "patients", " ", "with", "no", "detected", "APC", "mutation.", "Family", "1", "is", "the", "largest", "kindred", "in", "the", "Swedish", "Polyposis", "Registry;", "this", "family", "includes", "150", "individuals", "of", "whom", "57", "are", "affected", "by", "the", "disease", "(Figure", "6", "shows", "part", "of", "the", "pedigree).", "However,", "no", "pathogenic", "mutation", "had", "been", "detected", "after", "screening", "the", "whole", "coding", "region", "of", "the", "APC", "gene", "but", "as", "the", "family", "did", "show", "positive", "linkage", "to", "the", "APC", "locus", "we", "decided", "to", "perform", "expression", "analyses", "and", "evidence", "of", "lowered", "APC", "expression", "was", "obtained", "by", "quantitative", "real-time", "PCR", "(Figure", "5A).", "The", "result", "was", "supported", "by", "the", "indication", "of", "a", "lower", "expression", "from", "the", "T-allele", "from", "analysis", "of", "the", "APC", "c.5465A", ">", "T", "polymorphism", "in", "the", "cDNA", "sequencing", "diagram", "of", "two", "affected", "family", "members", "(Figure", "5B).", "The", "search", "for", "mutations", "in", "the", "DNA", "sequence", "of", "the", "APC", "promoters", "has", "been", "initiated,", "but", "no", "pathogenic", "change", "has", "been", "detected", "to", "this", "date.", "The", "possibility", "of", "the", "pathogenic", "change", "being", "epigenetic", "will", "have", "to", "be", "investigated", "further.", "Hypermethylation", "of", "CpG", "sites", "in", "the", "promoter", "of", "APC", "has", "been", "reported", "as", "a", "means", "of", "gene", "silencing", "in", "colorectal", "tumors", "[46-49].", "To", "the", "best", "of", "the", "authors'", "knowledge", "no", "germ-line", "inactivation", "of", "APC", "caused", "by", "promoter", "hypermethylation", "has", "been", "reported.", "However,", "cases", "of", "pathogenic", "germline", "epimutations", "have", "been", "identified", "in", "the", "MLH1", "gene,", "which", "causes", "hereditary", "non-polyposis", "CRC", "[50,51]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 9, 10, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The 61 different APC mutations listed in Additional file 2 were identified among 81 of the 96 families of the Swedish Polyposis Registry that were screened for APC mutations. Fifteen of the cases shown to be APC-mutation negative where all subjected to mutational screening of the MUTYH gene and six of them were shown to carry biallelic MUTYH mutations (reported in Kanter Smoler et al[31]). The overall mutation-detection rate in APC and MUTYH among the families in our study was thus 90%. In total, 84% of the families carried APC mutations while 6% where positive for biallelic MUTYH mutations. The mutation-detection rate we have reached in this study is notably high. In fact, a disease-causing mutation was detected in all cases who presented with a classical FAP phenotype (except for family 1 (C152), where we have clear indications for inactivation of the APC transcription). The mutation-negative patients all display an attenuated form of disease. However, as we have also found subtle mutations in the APC gene in patients mutation-negative patients patients with no detected APC mutation. Family 1 is the largest kindred in the Swedish Polyposis Registry; this family includes 150 individuals of whom 57 are affected by the disease (Figure 6 shows part of the pedigree). However, no pathogenic mutation had been detected after screening the whole coding region of the APC gene but as the family did show positive linkage to the APC locus we decided to perform expression analyses and evidence of lowered APC expression was obtained by quantitative real-time PCR (Figure 5A). The result was supported by the indication of a lower expression from the T-allele from analysis of the APC c.5465A > T polymorphism in the cDNA sequencing diagram of two affected family members (Figure 5B). The search for mutations in the DNA sequence of the APC promoters has been initiated, but no pathogenic change has been detected to this date. The possibility of the pathogenic change being epigenetic will have to be investigated further. Hypermethylation of CpG sites in the promoter of APC has been reported as a means of gene silencing in colorectal tumors [46-49]. To the best of the authors' knowledge no germ-line inactivation of APC caused by promoter hypermethylation has been reported. However, cases of pathogenic germline epimutations have been identified in the MLH1 gene, which causes hereditary non-polyposis CRC [50,51].
3034663-03-Methods-p01
[ "We", "genotyped", "the", "p.Lys618Ala", "variant", "in", "MLH1", "in", "1034", "individuals", "(373", "sporadic", "CRC", "patients,", "250", "index", "subjects", "from", "families", "suspected", "of", "having", "LS", "[revised", "Bethesda", "Guidelines]", "and", "411", " ", "controls).", "The", "controls", "were", "selected", "from", "the", "same", "hospitals,", "had", "no", "personal", "histories", "of", "cancer", "and", "had", "diagnoses", "unrelated", "to", "the", "variables", "of", "interest.", "They", "were", "matched", "for", "age,", "gender", "and", "race/ethnicity", "with", "the", "sporadic", "CRC", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We genotyped the p.Lys618Ala variant in MLH1 in 1034 individuals (373 sporadic CRC patients, 250 index subjects from families suspected of having LS [revised Bethesda Guidelines] and 411 controls). The controls were selected from the same hospitals, had no personal histories of cancer and had diagnoses unrelated to the variables of interest. They were matched for age, gender and race/ethnicity with the sporadic CRC patients.
3034663-04-Results-p01
[ "Pedigree", "for", "Family", "#1", "(CRC:", "Colorectal", "cancer;", "GC:", "Gastric", "cancer;", "DC:", "Duodenal", "cancer)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Pedigree for Family #1 (CRC: Colorectal cancer; GC: Gastric cancer; DC: Duodenal cancer).
1601966-03-Results-p03
[ "8q11.23-q21.13" ]
[ 0 ]
8q11.23-q21.13
2386495-05-Discussion-p02
[ "Large", "deletions", "of", "the", "APC", "gene" ]
[ 0, 0, 0, 0, 0, 0 ]
Large deletions of the APC gene
1360090-03-Results-p01
[ "Associations", "between", "BRAF", "mutation", "and", "molecular", "features", "of", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Associations between BRAF mutation and molecular features of colorectal cancer.
1334229-01-Abstract-p01
[ "Abstract" ]
[ 0 ]
Abstract
1557864-02-Background-p01
[ "If", "it", "would", "be", "possible", "to", "predict", "primary", "platinum", "resistance,", "patients", "might", "be", "spared", "an", "ineffective", "but", "toxic", "platinum-containing", "therapy", "and", "might", "benefit", "from", "an", "early", "therapy", "with", "different", "drugs.", "Recently,", "several", "molecular", "profiling", "studies,", "including", "our", "study,", "have", "revealed", "gene", "sets", "that", "can", "predict", "response", "to", "platinum-based", "chemotherapy", "in", "ovarian", "cancer", "[4-6].", "We", "discovered", "a", "nine-gene", "set", "which", "predicts", "response", "with", "a", "sensitivity", "of", "89%", "and", "a", "specificity", "of", "59%", "[5].", "One", "of", "these", "nine", "genes", "was", "proliferating", "cell", "nuclear", "antigen", "(PCNA).", "PCNA", "is", "a", "DNA", "sliding", "clamp", "that", "interacts", "with", "several", "proteins", "involved", "in", "cell", "cycle", "control,", "DNA", "methylation,", "DNA", "replication", "and", "DNA", "repair", "including", "mismatch", "repair", "[7].", "In", "this", "study,", "we", "have", "focused", "on", "DNA", "mismatch", "repair", "and", "its", "role", "in", "platinum-based", "chemotherapy", "resistance", "in", "ovarian", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
If it would be possible to predict primary platinum resistance, patients might be spared an ineffective but toxic platinum-containing therapy and might benefit from an early therapy with different drugs. Recently, several molecular profiling studies, including our study, have revealed gene sets that can predict response to platinum-based chemotherapy in ovarian cancer [4-6]. We discovered a nine-gene set which predicts response with a sensitivity of 89% and a specificity of 59% [5]. One of these nine genes was proliferating cell nuclear antigen (PCNA). PCNA is a DNA sliding clamp that interacts with several proteins involved in cell cycle control, DNA methylation, DNA replication and DNA repair including mismatch repair [7]. In this study, we have focused on DNA mismatch repair and its role in platinum-based chemotherapy resistance in ovarian cancer.
2386495-04-Results-p02
[ "Detection", "of", "the", "mosaic", "c.2700_2701delTC", "mutation", "in", "patient", "C107.", "Nucleotide", "2700", "is", "indicated", "with", "an", "arrow.", "(A)", "The", "aberrant", "bands", "indicated", "by", "the", "bracket", "were", "excised", "from", "the", "SSCP/HD", "gel.", "The", "resulting", "DNA", "sequence", "is", "shown", "to", "the", "right.", "(B)", "DNA", "sequence", "from", "DNA", "extracted", "from", "tumor-derived", "cells", "from", "the", "patient.", "(C)", "The", "DNA", "sequence", "from", "DNA", "isolated", "from", "the", "patient's", "blood", "lymphocytes", "Three", "2136", "3765", ",", "c.423-1662_531+1825del3595,", "was", "detected", "by", "RNA-based", "PTT", "with", "subsequent", "cDNA", "sequencing", "and", "verified", "by", "long-range", "PCR", "on", "genomic", "DNA.", "We", "could", "not", "detect", "this", "deletion", "with", "MLPA", "even", "though", "a", "probe", "for", "exon", "4", "is", "included", "in", "the", "MLPA", "kit", "(see", "the", "discussion).", "Detection", "of", "the", "large", "deletion", "in", "patient", "C591", "large", "deletion", " ", "in", "patient", "C591,", "encompassing", "APC", "exons", "13", "through", "the", "5'", "part", "of", "exon", "15,", "was", "carried", "out", "with", "MLPA.", "The", "deletion", "in", "patient", "2136", "was", "identified", "by", "PTT", "and", "subsequent", "DNA", "sequencing." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 4, 11, 9, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 5, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Detection of the mosaic c.2700_2701delTC mutation in patient C107. Nucleotide 2700 is indicated with an arrow. (A) The aberrant bands indicated by the bracket were excised from the SSCP/HD gel. The resulting DNA sequence is shown to the right. (B) DNA sequence from DNA extracted from tumor-derived cells from the patient. (C) The DNA sequence from DNA isolated from the patient's blood lymphocytes Three 2136 3765 , c.423-1662_531+1825del3595, was detected by RNA-based PTT with subsequent cDNA sequencing and verified by long-range PCR on genomic DNA. We could not detect this deletion with MLPA even though a probe for exon 4 is included in the MLPA kit (see the discussion). Detection of the large deletion in patient C591 large deletion in patient C591, encompassing APC exons 13 through the 5' part of exon 15, was carried out with MLPA. The deletion in patient 2136 was identified by PTT and subsequent DNA sequencing.
1619718-05-Discussion-p01
[ "In", "previous", "studies", "of", "KRAS", "in", "colorectal", "adenomas,", "mutation", "has", "been", "associated", "negatively", "with", "flat", "and", "depressed", "TAs", "and", "positively", "with", "polypoid", "appearance,", "increasing", "size,", "dysplasia,", "villous", "change", "and", "synchronous", "colorectal", "cancer.6,33–35", "In", "by", "far", "the", "largest", "study,", "which", "included", "738", "adenomas", "obtained", "from", "639", "participants", "in", "a", "dietary", "intervention", "trial,", "multivariate", "analysis", "showed", "that", "the", "independent", "predictors", "of", "KRAS", "mutation", "were", "age", "of", "subject,", "presence", "of", "villous", "architecture", "and", "high-grade", "dysplasia,", "but", "not", "size", "of", "adenoma.6", "It", "is", "well", "known", "that", "adenoma", "size,", "dysplasia", "and", "villous", "architecture", "are", "interrelated", "and", "account", "has", "to", "be", "taken", "of", "this", "in", "assessing", "results.", "In", "this", "study", "KRAS", "mutation", "occurred", "with", "the", "same", "frequency", "in", "small", "(18%)", "and", "large", "(17%)", "adenomas", "but", "was", "significantly", "more", "frequent", "in", "adenomas", "that", "included", "a", "villous", "architecture", "(50%).", "A", "previous", "study", "showed", "a", "very", "high", "frequency", "of", "KRAS", "mutation", "(93%)", "in", "flat", "adenomas", "with", "a", "tubulovillous", "architecture.34", "We", "would", "agree", "with", "the", "suggestion", "that", "KRAS", "mutation", "is", "linked", "with", "the", "development", "of", "villous", "change", "and", "does", "not", "influence", "adenoma", "growth", "in", "an", "independent", "manner.6", "In", "this", "study,", "high-grade", "dysplasia", "was", "diagnosed", "only", "when", "it", "amounted", "to", "carcinoma", "in", "situ.", "This", "was", "observed", "in", "none", "of", "the", "84", "adenomas", "but", "in", "four", "serrated", "polyps,", "of", "which", "three", "showed", "aberrant", "expression", "of", "p53", "and", "the", "fourth", "had", "KRAS", "mutation.", "Age", "was", "not", "a", "predictor", "of", "KRAS", "mutation", "in", "this", "study.", "However,", "many", "of", "the", "patients", "were", "undergoing", "continuing", "colonoscopic", "surveillance", "for", "colorectal", "polyps", "and", "it", "is", "known", "that", "after", "clearance", "of", "large", "polyps,", "time", "is", "required", "for", "the", "growth", "of", "newly", "initiated", "polyps.36", "This", "could", "explain", "why", "adenomas", "were", "smaller", "in", "subjects", "aged", ">", " ", "60", "years", "than", "in", "subjects", "aged", "<", " ", "60", "years", "adenomas", " ", "could", "be", "spurious", "and", "the", "true", "incidence", "of", "BRAF", "mutation", "in", "colorectal", "adenomas", "could", "be", "lower", "than", "4.8%.", "BRAF", "mutation", "frequencies", "of", "0%14", "and", "3%31", "have", "been", "reported", "in", "other", "series", "of", "colorectal", "adenomas." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In previous studies of KRAS in colorectal adenomas, mutation has been associated negatively with flat and depressed TAs and positively with polypoid appearance, increasing size, dysplasia, villous change and synchronous colorectal cancer.6,33–35 In by far the largest study, which included 738 adenomas obtained from 639 participants in a dietary intervention trial, multivariate analysis showed that the independent predictors of KRAS mutation were age of subject, presence of villous architecture and high-grade dysplasia, but not size of adenoma.6 It is well known that adenoma size, dysplasia and villous architecture are interrelated and account has to be taken of this in assessing results. In this study KRAS mutation occurred with the same frequency in small (18%) and large (17%) adenomas but was significantly more frequent in adenomas that included a villous architecture (50%). A previous study showed a very high frequency of KRAS mutation (93%) in flat adenomas with a tubulovillous architecture.34 We would agree with the suggestion that KRAS mutation is linked with the development of villous change and does not influence adenoma growth in an independent manner.6 In this study, high-grade dysplasia was diagnosed only when it amounted to carcinoma in situ. This was observed in none of the 84 adenomas but in four serrated polyps, of which three showed aberrant expression of p53 and the fourth had KRAS mutation. Age was not a predictor of KRAS mutation in this study. However, many of the patients were undergoing continuing colonoscopic surveillance for colorectal polyps and it is known that after clearance of large polyps, time is required for the growth of newly initiated polyps.36 This could explain why adenomas were smaller in subjects aged >   60 years than in subjects aged <   60 years adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
1619718-01-Abstract-p01
[ "To", "establish", "and", "explain", "the", "pattern", "of", "molecular", "signatures", "across", "colorectal", "polyps." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
To establish and explain the pattern of molecular signatures across colorectal polyps.
2386495-04-Results-p01
[ "Mutation", "spectrum", "of", "the", "APC", "gene.", "(A)", "The", "spectrum", "of", "APC", " ", "mutations", "identified", "among", "families", "from", "the", "Swedish", "Polyposis", "Registry", "showing", "the", "distribution", "between", "previously", "reported", "and", "novel", "mutations", "in", "our", "patients.", "(B)", "A", "schematic", "representation", "of", "the", "APC", "APC", " ", "gene", "which", "predicts", "a", "severe", "phenotype", "[36]", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Available", "data", "on", "colorectal", "polyp", " ", "number", "shows", "that,", "in", "spite", "of", "higher", "age", "at", "diagnosis,", "dense", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", "(44%)", "had", "cancer", "at", "diagnosis.", "The", "median", "age", "in", "this", "group", "was", "47.5", "(range", "45–51)", "years", "and", "none", "had,", "despite", "high", "age", "at", "diagnosis", "of", "CRC,", "dense", "colorectal", "polyposis", "at", "diagnosis", "indicating", "a", "less-severe", "phenotype.", "A", "compilation", "of", "clinical", "status", "of", "all", "patients", "analyzed", "in", "this", "study", "is", "shown", "in", "Additional", "file", "1." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation spectrum of the APC gene. (A) The spectrum of APC mutations identified among families from the Swedish Polyposis Registry showing the distribution between previously reported and novel mutations in our patients. (B) A schematic representation of the APC APC gene which predicts a severe phenotype [36] had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Available data on colorectal polyp number shows that, in spite of higher age at diagnosis, dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine (44%) had cancer at diagnosis. The median age in this group was 47.5 (range 45–51) years and none had, despite high age at diagnosis of CRC, dense colorectal polyposis at diagnosis indicating a less-severe phenotype. A compilation of clinical status of all patients analyzed in this study is shown in Additional file 1.
1334229-04-Results-p01
[ "Of", "656", "tumours", "for", "which", "the", "other", "molecular", "alterations,", "i.e.", "mutations", "in", "the", "APC", "and", "K-ras", "genes", "and", "hMLH1", "expression,", "were", "all", "successfully", "and", "completely", "analysed,", "103", "colorectal", "tumours", "did", "not", "harbour", "a", "truncating", "or", "missense", "APC", "mutation", "colorectal", " ", "tumours", " ", "did", "not", "harbour", "a", "truncating", "or", "missense", "APC", "mutation,", "an", "activating", "K-ras", "mutation", "or", "showed", "lack", "of", "hMLH1", "expression,", "as", "depicted", "in", "figure", "1.", "Truncating", "as", "well", "as", "missense", "APC", "mutations", " ", "and", "activating", "K-ras", "mutations", "were", "relatively", "common.", "Truncating", "APC", "mutations", "alone", "and", "activating", "K-ras", "mutations", "in", "codons", "12", "and", "13", "only,", "occurred", "at", "similar", "frequencies", "(20%", "(130/656)", "and", "18%", "(121/656),", "respectively).", "A", "combination", "of", "a", "truncating", "mutation", "in", "APC", "and", "an", "activating", "mutation", "in", "K-ras", "occurred", "less", "often", "than", "the", "sole", "occurrences", "of", "mutations", "in", "both", "genes.", "However,", "as", "shown", "in", "table", "2,", "the", "simultaneous", "occurrence", "of", "mutations", "in", "both", "genes", "occurred", "more", "frequently", "than", "expected", "on", "the", "basis", "of", "chance", "alone.", "A", "χ2", "test", "for", "the", "occurrence", "of", "a", "truncating", "APC", "mutation", "and", "an", "activating", "K-ras", "mutation", "revealed", "that", "the", "occurrence", "of", "these", "mutations", "was", "not", "independent", "(χ2", "=", "8.7,", "P", "<", "0.001),", "but", "the", "correlation", "was", "weak", "(Cramérs", "V", "=", "0.138).", "Finally,", "although", "11", "tumours", "that", "harboured", "a", "mutation", "activating", "K-ras", "mutation", "cancers", ",", "a", "CTNNB1", "mutation", "that", "would", "lead", "to", "loss", "of", "one", "of", "the", "Ser/Thr", "phosphorylation", "sites", "and", "subsequent", "stabilisation", "of", "the", "protein,", "occurred", "at", "codons", "37", "and", "45,", "all", "were", "C→T", " ", "transitions,", "leading", "to", "Ser→Phe", "amino", "acid", "changes", "and", "occurred", "in", "the", "proximal", "colon.", "All", "bar", "one", "also", "had", "an", "activating", "mutation", "in", "the", "K-ras", "gene.", "Three", "of", "these", "five", "tumours", "showed", "hMLH1", "deficiency.", "Two", "colorectal", "cancer", "patients", "harboured", "a", "mutation", "in", "the", "CTNNB1", "gene,", "that", "did", "not", "occur", "at", "the", "Ser/Thr", "phosphorylation", "sites,", "but", "would", "result", "in", "an", "amino", "acid", "alteration", "at", "codons", "22", "and", "29,", "the", "effects", "of", "which", "are", "unknown.", "Because", "of", "the", "very", "low", "frequency", "of", "tumours", "harbouring", "a", "CTNNB1", "mutation,", "these", "mutations", "were", "not", "included", "in", "further", "analyses.", "In", "addition,", "mutation", "analysis", "of", "remaining", "samples", "was", "abandoned,", "since", "this", "was", "deemed", "irrelevant", "as", "these", "harboured", "truncating", "APC", "mutations", "and", "are", "considered", "to", "be", "unlikely", "to", "also", "have", "CTNNB1", "mutations", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 6, 6, 3, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 6, 6, 6, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 5, 6, 6, 1, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Of 656 tumours for which the other molecular alterations, i.e. mutations in the APC and K-ras genes and hMLH1 expression, were all successfully and completely analysed, 103 colorectal tumours did not harbour a truncating or missense APC mutation colorectal tumours did not harbour a truncating or missense APC mutation, an activating K-ras mutation or showed lack of hMLH1 expression, as depicted in figure 1. Truncating as well as missense APC mutations and activating K-ras mutations were relatively common. Truncating APC mutations alone and activating K-ras mutations in codons 12 and 13 only, occurred at similar frequencies (20% (130/656) and 18% (121/656), respectively). A combination of a truncating mutation in APC and an activating mutation in K-ras occurred less often than the sole occurrences of mutations in both genes. However, as shown in table 2, the simultaneous occurrence of mutations in both genes occurred more frequently than expected on the basis of chance alone. A χ2 test for the occurrence of a truncating APC mutation and an activating K-ras mutation revealed that the occurrence of these mutations was not independent (χ2 = 8.7, P < 0.001), but the correlation was weak (Cramérs V = 0.138). Finally, although 11 tumours that harboured a mutation activating K-ras mutation cancers , a CTNNB1 mutation that would lead to loss of one of the Ser/Thr phosphorylation sites and subsequent stabilisation of the protein, occurred at codons 37 and 45, all were C→T transitions, leading to Ser→Phe amino acid changes and occurred in the proximal colon. All bar one also had an activating mutation in the K-ras gene. Three of these five tumours showed hMLH1 deficiency. Two colorectal cancer patients harboured a mutation in the CTNNB1 gene, that did not occur at the Ser/Thr phosphorylation sites, but would result in an amino acid alteration at codons 22 and 29, the effects of which are unknown. Because of the very low frequency of tumours harbouring a CTNNB1 mutation, these mutations were not included in further analyses. In addition, mutation analysis of remaining samples was abandoned, since this was deemed irrelevant as these harboured truncating APC mutations and are considered to be unlikely to also have CTNNB1 mutations [7].
1601966-06-Methods-p05
[ "Restrictions", "to", "use", "by", "non-academics:", "none" ]
[ 0, 0, 0, 0, 0, 0 ]
Restrictions to use by non-academics: none
2386495-03-Methods-p01
[ "Patient", "C896,", "with", "only", "five", "adenomas,", "was", "included", "because", "of", "a", "family", "history", "of", "FAP.", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47.", "At", "diagnosis,", "10–20", "small", "(less", "than", "10", "mm)", "polyps", "were", "found", "in", "most", "colorectal", "parts.", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly.", "At", "age", "50,", "carcinoma", "(", "Dukes", "A", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47.", "At", "diagnosis,", "10–20", "small", "(less", "than", "10", "mm)", "polyps", "were", "found", "in", "most", "colorectal", "parts.", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly.", "At", "age", "50,", "carcinoma", "(Dukes", "A)", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "96", " ", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene.", "Twenty-four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", " ", "families", "remain", "to", "be", "tested.", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi-allelic", "MUTYH", "mutations", "[31].", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call-up", "patients,", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP.", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non-FAP", "related", "cause", "after", "the", "age", "of", "75.", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study.", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 23, 24, 19, 20, 20, 20, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 4, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma ( Dukes A family history of FAP . Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1.
3034663-03-Methods-p01
[ "Three", "characterized", "LS", "families", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria", "and", "that", "consisted", "of", "members", "with", "the", "p.Lys618Ala", "variant", "were", "included", "to", "assess", "co-occurrence", "and", "co-segregation.", "Two", "families", "attended", "the", "Genetic", "Counselling", "in", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals", "and", "one", "family", "was", "a", "member", "of", "the", "EPICOLON", "cohort", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three characterized LS families that fulfilled the Amsterdam II Criteria and that consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. Two families attended the Genetic Counselling in Cancer Units of the Elche and La Fe Hospitals and one family was a member of the EPICOLON cohort [7].
1557864-06-Conclusion-p01
[ "No", "MMR", "inactivation", "was", "detected", "in", "75", "ovarian", "carcinoma", "specimens", "and", "no", "association", "was", "seen", "between", "MMR", " ", "inactivation", "and", "resistance", "in", "the", "ovarian", "cancer", "cell", "lines", "as", "well", "as", "the", "ovarian", "carcinomas.", "We", "hypothesize", "that", "MMR", " ", "inactivation", "is", "not", "clearly", "associated", "with", "intrinsic", "resistance", "in", "ovarian", "cancer.", "However,", "it", "might", "play", "a", "role", "in", "acquired", "resistance", "due", "to", "selection", "of", "MMR", "MMR", " ", "inactivation", "was", "detected", "in", "75", " ", "ovarian", "carcinoma", "specimens", "and", "no", "association", "was", "seen", "between", "MMR", "inactivation", "and", "resistance", "in", "the", "ovarian", "cancer", "ovarian", " ", "carcinoma", "specimens", "and", "no", "association", "was", "seen", "between", "MMR", "inactivation", "and", "resistance", "in", "the", "ovarian", "cancer", "cell", "lines", "as", "well", "as", "the", "ovarian", "carcinomas.", "We", "hypothesize", "that", "MMR", "inactivation", "is", "not", "clearly", "associated", "with", "intrinsic", "resistance", "in", "ovarian", "cancer", "ovarian", "No", "MMR", "inactivation", " ", "was", "detected", "in", "75", "ovarian", "carcinoma", "specimens", "and", "no", "association", "was", "seen", "between", "MMR", "inactivation", "and", "resistance", "in", "the", "ovarian", " ", "cancer", "cell", "lines", "as", "well", "as", "the", "ovarian", "carcinoma", " ", "specimens", "and", "no", "association", "was", "seen", "between", "MMR", "inactivation", "and", "resistance", "in", "the", "ovarian", "cancer", "cell", "lines", "as", "well", "as", "the", "ovarian", "carcinomas", "cell", "lines", "specimens", " ", "and", "no", "association", "was", "seen", "between", "MMR", "inactivation", "and", "resistance", "in", "the", "ovarian", "cancer", "cell", "lines", "as", "well", "as", "the", "ovarian", "carcinomas.", "We", "hypothesize", "that", "MMR", "inactivation", "is", "not", "clearly", "associated", "with", "intrinsic", "resistance", "in", "ovarian", "cancer.", "However,", "it", "might", "play", "a", "role", "in", "acquired", "resistance", "due", "to", "selection", "of", "MMR", "deficient", "cells", "during", "platinum-based", "chemotherapy,", "but", "this", "needs", "further", "investigation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 3, 7, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 10, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
No MMR inactivation was detected in 75 ovarian carcinoma specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinomas. We hypothesize that MMR inactivation is not clearly associated with intrinsic resistance in ovarian cancer. However, it might play a role in acquired resistance due to selection of MMR MMR inactivation was detected in 75 ovarian carcinoma specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer ovarian carcinoma specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinomas. We hypothesize that MMR inactivation is not clearly associated with intrinsic resistance in ovarian cancer ovarian No MMR inactivation was detected in 75 ovarian carcinoma specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinoma specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinomas cell lines specimens and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinomas. We hypothesize that MMR inactivation is not clearly associated with intrinsic resistance in ovarian cancer. However, it might play a role in acquired resistance due to selection of MMR deficient cells during platinum-based chemotherapy, but this needs further investigation.
1334229-05-Discussion-p02
[ "The", "K-ras", "mutation", "frequency", "of", "37%", "is", "in", "accordance", "with", "reported", "frequencies", "of", "30", "to", "60%", "[33-43].", "The", "frequency", "of", "37%", "of", "truncating", "mutations", "in", "the", "mutation", "cluster", "region", "of", "APC", "in", "this", "study,", "however,", "seems", "low", "in", "comparison", "to", "the", "general", "assumption", "that", "most", "colorectal", "tumours", "harbour", "a", "mutation", "mutations", " ", "are", "derived", "from", "the", "study", "by", "Smith", "et", "al.", "[9],", "similar", "results,", "although", "not", "statistically", "significant,", "could", "be", "obtained." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 5, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The K-ras mutation frequency of 37% is in accordance with reported frequencies of 30 to 60% [33-43]. The frequency of 37% of truncating mutations in the mutation cluster region of APC in this study, however, seems low in comparison to the general assumption that most colorectal tumours harbour a mutation mutations are derived from the study by Smith et al. [9], similar results, although not statistically significant, could be obtained.
1619718-04-Results-p02
[ "With", "respect", "to", "the", "25", "serrated", "polyps", "with", "dysplasia,", "only", "five", "occurred", "in", "the", "proximal", "colon", "(up", "to", "the", "splenic", "flexure).", "Two", "60%", " ", "had", "either", "BRAF", "or", "KRAS", "mutation)", "(Table", "1).", "The", "frequent", "finding", "of", "either", "BRAF", "or", "KRAS", "mutations", "in", "both", "types", "of", "serrated", "polyp", "indicated", "that", "MPs", "and", "SAs", "might", "be", "heterogeneous", "lesions.", "These", "25", "serrated", "polyps", "with", "dysplasia", "were", "therefore", "grouped", "differently.", "Group", "A", "polyps", "(n", "=", "16)", "included", "a", "non-dysplastic", "serrated", "component", "and/or", "dysplastic", "epithelium", "in", "which", "the", "architectural", "and", "cytological", "changes", "were", "more", "reminiscent", "of", "HP", "than", "adenoma", "(Figure", "1A,B).", "Group", "B", "polyps", "(n", "=", "9)", "comprised", "serrated", "polyps", "in", "which", "the", "epithelial", "dysplasia", "appeared", "adenomatous", "(Figure", "1C,D).", "BRAF", "mutation", "occurred", "in", "10/16", "Group", "A", "polyps", "but", "only", "1/9", "Group", "B", "polyps", "(P", "<", "0.03).", "KRAS", "polyps", " ", "(P", "<", "0.03).", "KRAS", "mutation", "occurred", "in", "only", "3/16", "Group", "A", "polyps", "but", "in", "5/9", "Group", "B", "polyps", "(P", "=", "0.06).", "In", "each", "of", "the", "five", "Group", "B", "polyps", "with", "KRAS", "mutation,", "the", "adenomatous", "component", "showed", "both", "villous", "change", "and", "serration." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
With respect to the 25 serrated polyps with dysplasia, only five occurred in the proximal colon (up to the splenic flexure). Two 60% had either BRAF or KRAS mutation) (Table 1). The frequent finding of either BRAF or KRAS mutations in both types of serrated polyp indicated that MPs and SAs might be heterogeneous lesions. These 25 serrated polyps with dysplasia were therefore grouped differently. Group A polyps (n = 16) included a non-dysplastic serrated component and/or dysplastic epithelium in which the architectural and cytological changes were more reminiscent of HP than adenoma (Figure 1A,B). Group B polyps (n = 9) comprised serrated polyps in which the epithelial dysplasia appeared adenomatous (Figure 1C,D). BRAF mutation occurred in 10/16 Group A polyps but only 1/9 Group B polyps (P < 0.03). KRAS polyps (P < 0.03). KRAS mutation occurred in only 3/16 Group A polyps but in 5/9 Group B polyps (P = 0.06). In each of the five Group B polyps with KRAS mutation, the adenomatous component showed both villous change and serration.
2386495-04-Results-p01
[ "Results" ]
[ 0 ]
Results
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "MSI", "status", "in", "40", "cases,", "methylation", "status", "in", "83", "cases,", "KRAS", "mutation", "in", "26", "cases", "and", "TP53", "mutation", "in", "26", "cases" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for MSI status in 40 cases, methylation status in 83 cases, KRAS mutation in 26 cases and TP53 mutation in 26 cases
1601966-03-Results-p03
[ "8q11.23-q21.13" ]
[ 0 ]
8q11.23-q21.13
1619718-03-Materials-and-methods-p03
[ "Statistics" ]
[ 0 ]
Statistics
1334229-03-Methods-p02
[ "The", "semi-nested", "PCR", "products", "from", "samples", "without", "a", "truncating", "APC", "mutation", "microsatellite", "instable", " ", "tumours", "are", "also", "expected", "to", "more", "frequently", "have", "mutations", "in", "CTNNB1", "[26]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 19, 20, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The semi-nested PCR products from samples without a truncating APC mutation microsatellite instable tumours are also expected to more frequently have mutations in CTNNB1 [26].
1557864-05-Discussion-p01
[ "Next", "we", "studied", "the", "association", "between", "MMR", "inactivation", "and", "cisplatin", "resistance", "in", "these", "cell", "lines.", "MMR", "inactivation", "seen", "in", "SKOV3", "and", "2774", "might", "result", "in", "the", "relative", "resistance", "to", "cisplatin", "compared", "to", "the", "other", "cell", "lines.", "On", "the", "other", "hand,", "A2780", "which", "has", "clearly", "an", "inactive", "MMR,", "was", "most", "sensitive", "to", "cisplatin.", "Overall,", "there", "seems", "to", "be", "no", "association", "between", "the", "response", "to", "cisplatin", "and", "MMR", "MMR", "MMR", "inactivation", " ", "in", "ovarian", "cancer,", "and", "2)", "is", "it", "associated", "with", "platinum-based", "chemotherapy", "response." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 19, 20, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Next we studied the association between MMR inactivation and cisplatin resistance in these cell lines. MMR inactivation seen in SKOV3 and 2774 might result in the relative resistance to cisplatin compared to the other cell lines. On the other hand, A2780 which has clearly an inactive MMR, was most sensitive to cisplatin. Overall, there seems to be no association between the response to cisplatin and MMR MMR MMR inactivation in ovarian cancer, and 2) is it associated with platinum-based chemotherapy response.
1557864-03-Methods-p01
[ "The", "MTT", "colorimetric", "assay,", "which", "measures", "the", "number", "of", "viable", "cells", "capable", "of", "reducing", "the", "tetrazolium", "compound", "(Sigma-Aldrich,", "Zwijndrecht,", "The", "Netherlands)", "to", "a", "blue", "formazan", "product,", "was", "used", "to", "quantitate", "the", "chemosensitivity", "of", "the", "ovarian", " ", "cancer", "cell", "lines", "to", "cisplatin.", "The", "assay", "was", "performed", "as", "described", "previously", "by", "us", "[38]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The MTT colorimetric assay, which measures the number of viable cells capable of reducing the tetrazolium compound (Sigma-Aldrich, Zwijndrecht, The Netherlands) to a blue formazan product, was used to quantitate the chemosensitivity of the ovarian cancer cell lines to cisplatin. The assay was performed as described previously by us [38].
1266026-04-Results-p01
[ "Ages", "at", "cancer", "can", "be", "used", "to", "estimate", "likely", "numbers", "of", "oncogenic", "mutations", "required", "before", "transformation", "[3-6,11].", "Average", "ages", "for", "sporadic", "MSI+", "87.6%", ")", "MSI-", "cancers", "and", "127", "(12.4%)", "MSI+", "cancers.", "The", "MSI+", "cancers", "were", "further", "classified", "as", "sporadic", "(N", "=", "98", "or", "9.6%", "of", "all", "cancers)", "or", "HNPCC", "(N", "=", "29", "or", "2.9%", "of", "all", "cancers)", "based", "on", "germline", "MLH1", "or", "MSH2", "mutations", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 10, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Ages at cancer can be used to estimate likely numbers of oncogenic mutations required before transformation [3-6,11]. Average ages for sporadic MSI+ 87.6% ) MSI- cancers and 127 (12.4%) MSI+ cancers. The MSI+ cancers were further classified as sporadic (N = 98 or 9.6% of all cancers) or HNPCC (N = 29 or 2.9% of all cancers) based on germline MLH1 or MSH2 mutations (Table 1).
1266026-05-Discussion-p01
[ "An", "epigenetic", "mechanism", "may", "help", "explain", "why", "sporadic", "MSI+", "cancers", "require", "more", "than", "one", "additional", "somatic", "alteration", "relative", "to", "HNPCC", "cancers.", "Inactivation", "of", "the", "normal", "MMR", "allele", "occurs", "through", "mutation", "(usually", "LOH", "[15])", "in", "HNPCC", "whereas", "MMR", "loss", " ", "in", "sporadic", " ", "MSI+", " ", "cancers", " ", "is", "associated", "with", "MLH1", "promoter", "methylation", "[16,17].", "CpG", "islands", "may", "be", "\"protected\"", "from", "methylation", "because", "most", "are", "unmethylated", "at", "birth", "and", "usually", "remain", "unmethylated", "throughout", "life", "[18].", "Epigenetic", "MLH1", "inactivation", "may", "require", "at", "least", "two", "cis", "acting", "somatic", "alterations---loss", "of", "a", "mechanism", "that", "normally", "prevents", "methylation,", "followed", "by", "the", "accumulation", "of", "methylation", "at", "sufficient", "numbers", "of", "CpG", "sites", "to", "silence", "expression." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 0, 0, 17, 0, 19, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
An epigenetic mechanism may help explain why sporadic MSI+ cancers require more than one additional somatic alteration relative to HNPCC cancers. Inactivation of the normal MMR allele occurs through mutation (usually LOH [15]) in HNPCC whereas MMR loss in sporadic MSI+ cancers is associated with MLH1 promoter methylation [16,17]. CpG islands may be "protected" from methylation because most are unmethylated at birth and usually remain unmethylated throughout life [18]. Epigenetic MLH1 inactivation may require at least two cis acting somatic alterations---loss of a mechanism that normally prevents methylation, followed by the accumulation of methylation at sufficient numbers of CpG sites to silence expression.
1619718-05-Discussion-p02
[ "Serrated", "polyps", "with", "dysplasia,", "i.e.", "MPs", "and", "SAs,", "together", "comprised", "only", "2%", "of", "the", "overall", "consecutive", "series", "of", "1250", "polyps.", "While", "mutation", "of", "KRAS", "and", "BRAF", "was", "associated", "with", "conventional", "adenoma", "and", "SSA,", "respectively", "(see", "above),", "BRAF", "and", "KRAS", "mutation", "occurred", "with", "similar", "frequency", "in", "both", "MPs", "(40%", "and", "50%,", "respectively)", "and", "SAs", "(33%", "and", "27%,", "respectively).", "In", "the", "literature,", "the", "frequency", "of", "BRAF", "and", "KRAS", "mutation", "in", "MP", "or", "SA", "has", "ranged", "from", "36", "to", "100%", "and", "from", "0%", "to", "60%,", "respectively.12,16,39–42", "These", "findings", "indicate", "that", "this", "subset", "of", "colorectal", "polyps", "is", "likely", "to", "be", "heterogeneous", "in", "terms", "of", "its", "molecular", "origins.", "These", "polyps", "were", "therefore", "reclassified", "according", "to", "their", "resemblance", "to", "HP", "or", "SSA", "(Group", "A)", "(Figure", "1A,B,E,F)", "or", "to", "conventional", "adenoma", "(Group", "B)", "(Figure", "1C,D).", "Particular", "histological", "features", "among", "the", "Group", "A", "polyps", "were:", "marked", "serration", "BRAF", " ", "mutation", "occurs", "more", "frequently", "in", "the", "microvesicular", "variant", "of", "HP.16", "By", "contrast,", "KRAS", "mutation", "occurs", "much", "more", "commonly", "in", "the", "goblet", "cell", "variant", "of", "HP,", "which", "is", "usually", "small,", "located", "in", "the", "left", "colon", "or", "rectum", "and", "deviates", "minimally", "from", "normal", "colorectal", "mucosa", "in", "terms", "of", "differentiation", "and", "architecture.16,25", "The", "latter", "were", "under-represented", "in", "this", "series", "(details", "not", "shown)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 18, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Serrated polyps with dysplasia, i.e. MPs and SAs, together comprised only 2% of the overall consecutive series of 1250 polyps. While mutation of KRAS and BRAF was associated with conventional adenoma and SSA, respectively (see above), BRAF and KRAS mutation occurred with similar frequency in both MPs (40% and 50%, respectively) and SAs (33% and 27%, respectively). In the literature, the frequency of BRAF and KRAS mutation in MP or SA has ranged from 36 to 100% and from 0% to 60%, respectively.12,16,39–42 These findings indicate that this subset of colorectal polyps is likely to be heterogeneous in terms of its molecular origins. These polyps were therefore reclassified according to their resemblance to HP or SSA (Group A) (Figure 1A,B,E,F) or to conventional adenoma (Group B) (Figure 1C,D). Particular histological features among the Group A polyps were: marked serration BRAF mutation occurs more frequently in the microvesicular variant of HP.16 By contrast, KRAS mutation occurs much more commonly in the goblet cell variant of HP, which is usually small, located in the left colon or rectum and deviates minimally from normal colorectal mucosa in terms of differentiation and architecture.16,25 The latter were under-represented in this series (details not shown).
3034663-04-Results-p01
[ "There", "were", "no", "significant", "associations", "in", "the", "case-control", "and", "case-case", "studies", "(80%", "detection", "power,", "OR", "=", "3.0;", "two-sided", "test,", "alpha", "level", "=", "5%)", "(Table", "2)", "and", "no", "statistically", "significant", "associations", "when", "the", "OR", "was", "adjusted", "for", "age", "and", "sex." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
There were no significant associations in the case-control and case-case studies (80% detection power, OR = 3.0; two-sided test, alpha level = 5%) (Table 2) and no statistically significant associations when the OR was adjusted for age and sex.
2386495-05-Discussion-p03
[ "Screening", "for", "mosaic", "mutations", "in", "the", "three", "APC-", "and", "MUTYH-negative", "patients", "with", "de", "novo", "mutations", "revealed", "the", "c.2700_2701delTC", "mutation", "in", "patient", "C107.", "This", "mutation", "was", "detected", "in", "a", "very", "low", "fraction", "of", "the", "lymphocytes", "and", "was", "only", "detectable", "using", "the", "SSCP/HD", "analysis", "(Figure", "2A).", "Owing", "to", "the", "subtle", "appearance", "of", "this", "mutation", "it", "could", "easily", "have", "been", "overlooked." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Screening for mosaic mutations in the three APC- and MUTYH-negative patients with de novo mutations revealed the c.2700_2701delTC mutation in patient C107. This mutation was detected in a very low fraction of the lymphocytes and was only detectable using the SSCP/HD analysis (Figure 2A). Owing to the subtle appearance of this mutation it could easily have been overlooked.
1373649-02-Background-p01
[ "Since", "there", "are", "no", "premonitory", "signs", "of", "susceptibility", "to", "HNPCC,", "family", "history", "has", "been", "the", "primary", "method", "for", "identifying", "patients", "at", "risk.", "Defined", "by", "the", "International", "Collaborative", "group", "on", "HNPCC,", "the", "typical", "HNPCC", "family", "fulfill", "the", "following", "criteria", "(referred", "to", "as", "the", "Amsterdam-I", "criteria", "[3]):", "1.", "Three", "or", "more", "relatives", "with", "histologically", "verified", "colorectal", " ", "cancer,", "one", "of", "whom", "is", "a", "first-degree", "relative", "of", "the", "other", "two;", "2.", "Colorectal", "cancer", "affecting", "at", "least", "2", "successive", "generations;", "and", "3.", "At", "least", "one", "relative", "diagnosed", "with", "colorectal", "cancer", "under", "the", "age", "of", "50.", "The", "fulfillment", "of", "these", "criteria", "prompted", "further", "genetics", "investigations.", "More", "recently", "it", "has", "been", "revised", "to", "take", "into", "account", "the", "prevalence", "of", "extracolonic", "cancer", " ", "in", "certain", "HNPCC", "families", "[4]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 0, 0, 0, 0, 0, 0 ]
Since there are no premonitory signs of susceptibility to HNPCC, family history has been the primary method for identifying patients at risk. Defined by the International Collaborative group on HNPCC, the typical HNPCC family fulfill the following criteria (referred to as the Amsterdam-I criteria [3]): 1. Three or more relatives with histologically verified colorectal cancer, one of whom is a first-degree relative of the other two; 2. Colorectal cancer affecting at least 2 successive generations; and 3. At least one relative diagnosed with colorectal cancer under the age of 50. The fulfillment of these criteria prompted further genetics investigations. More recently it has been revised to take into account the prevalence of extracolonic cancer in certain HNPCC families [4].
3034663-05-Discussion-p01
[ "Unfortunately,", "genetic", "testing", "for", "hereditary", "cancer", "frequently", "fails", "to", "identify", "unambiguous", "deleterious", "variants.", "Erroneous", "classification", "of", "a", "genetic", "variant", "may", "have", "a", "great", "effect", "on", "at-risk", "familial", "who", "undergo", "genetic", "testing", "for", "risk", "prediction", "because", "it", "results", "in", "incorrect", "clinical", "recommendations." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Unfortunately, genetic testing for hereditary cancer frequently fails to identify unambiguous deleterious variants. Erroneous classification of a genetic variant may have a great effect on at-risk familial who undergo genetic testing for risk prediction because it results in incorrect clinical recommendations.
2386495-05-Discussion-p02
[ "The", "fraction", "of", "large", "deletions", "of", "all", "APC", "mutations", "identified", "in", "the", "Swedish", "patients", "was", "9%,", "which", "is", "higher", "than", "the", "5%", "of", "large", "deletions", "reported", "in", "[38].", "The", "relatively", "large", "number", "of", "gross", "deletions", "identified", "could", "be", "a", "result", "of", "the", "thorough", "analysis", "applied", "for", "every", "patient,", "including", "the", "use", "of", "the", "MLPA", "technique.", "It", "is", "noteworthy", "that", "no", "deletion", "of", "APC", "exon", "4", "in", "patient", "3765", "deletion", "of", "APC", "exon", "4", "100–1000", "polyps", ",", "46", "years", "of", "age", "at", "diagnosis).", "In", "family", "1", "(reduced", "expression", "of", "APC),", "patient", "C152", "displayed", "a", "classical", "FAP", "phenotype", "including", "a", "large", "number", "of", "polyps,", "duodenal", "adenomas,", "and", "fundic", "gland", "polyps", "(Additional", "file", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 5, 6, 6, 6, 6, 17, 18, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The fraction of large deletions of all APC mutations identified in the Swedish patients was 9%, which is higher than the 5% of large deletions reported in [38]. The relatively large number of gross deletions identified could be a result of the thorough analysis applied for every patient, including the use of the MLPA technique. It is noteworthy that no deletion of APC exon 4 in patient 3765 deletion of APC exon 4 100–1000 polyps , 46 years of age at diagnosis). In family 1 (reduced expression of APC), patient C152 displayed a classical FAP phenotype including a large number of polyps, duodenal adenomas, and fundic gland polyps (Additional file 1).
2386495-02-Background-p01
[ "Different", "genotype-phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[26-28].", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene.", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "of", "disease", "with", "early", "onset", "and", "profuse", "polyposis.", "The", "milder,", "attenuated", "form", "of", "disease", "(AFAP),", "characterized", "by", "less", "than", "100", "adenomas", "and", "later", "onset", "of", "adenomatosis", "and", "CRC", "MUTYH-associated", "CRC", " ", "(MIM#608456).", "MAP", "is", "caused", "by", "biallelic", "mutations", "in", "the", "MUTYH", "(mutY", "homologue;", "MIM*604933)", "gene", "(1p32.1-p34.3)", "and", "is", "inherited", "in", "a", "recessive", "manner", "[4,5]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5].
1360090-02-Background-p01
[ "Although", "the", "positive", "association", "with", "MSI+", "and", "inverse", "association", "with", "KRAS", "mutation", "MLH1", " ", "promoter", "methylation", "and", "do", "not", "occur", "in", "MSI+", "tumors", "from", "hereditary", "non-polyposis", "colorectal", "cancer", "(HNPCC)", "patients", "[5,8-10],", "thus", "providing", "a", "convenient", "discriminator", "between", "sporadic", "and", "familial", "cases.", "The", "majority", "of", "MSI+", "sporadic", "tumors", "belong", "to", "a", "larger", "CRC", "group", "referred", "to", "as", "the", "CpG", "island", "methylator", "phenotype", "(CIMP+)", "that", "is", "characterised", "by", "widespread", "hypermethylation", "of", "CpG", "islands", "located", "with", "gene", "promoter", "regions", "[11].", "Both", "MSI+", "and", "CIMP+", "tumors", "are", "thought", "to", "arise", "from", "large", "hyperplastic", "polyps", "and", "serrated", "adenomas", "[12,13]", "and", "recent", "work", "has", "demonstrated", "a", "high", "frequency", "of", "BRAF", "mutations", "in", "these", "lesions", "[7,14,15]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Although the positive association with MSI+ and inverse association with KRAS mutation MLH1 promoter methylation and do not occur in MSI+ tumors from hereditary non-polyposis colorectal cancer (HNPCC) patients [5,8-10], thus providing a convenient discriminator between sporadic and familial cases. The majority of MSI+ sporadic tumors belong to a larger CRC group referred to as the CpG island methylator phenotype (CIMP+) that is characterised by widespread hypermethylation of CpG islands located with gene promoter regions [11]. Both MSI+ and CIMP+ tumors are thought to arise from large hyperplastic polyps and serrated adenomas [12,13] and recent work has demonstrated a high frequency of BRAF mutations in these lesions [7,14,15].
1373649-03-Methods-p01
[ "As", "screening", "method", "for", "HNPCC", "we", "searched", "for", "MSI", "in", "the", "proband's", "primary", "tumor", "and", "metastasis", "tissue", "blocks.", "The", "absence", "of", "proband's", "non-tumor", "DNA", "for", "MSI", "testing", "was", "overcome", "studying", "the", "alleles", "carried", "by", "his", "progenitors.", "Once", "the", "MSI", "was", "established,", "a", "second", "blood", "sample", "was", "obtained", "from", "the", "proband's", "mother", "(obligate", "carrier", "but", "at", "the", "moment", "of", "the", "study", "still", "unaffected)", "to", "full", "mutation", "analysis", "of", "the", "hMSH2", "and", "hMLH1", "genes", "by", "direct", "sequencing.", "After", "identifying", "the", "family", "mutation,", "we", "searched", "it", "in", "both", "proband's", "sisters", "sisters", ")", "of", "a", "male", "who", "died", "of", "poorly", "differentiated", "colorectal", "adenocarcinoma", "at", "age", "23", "contacted", "us", "for", "genetic", "counseling.", "A", "detailed", "family", "and", "medical", "history", "was", "obtained", "through", "interview", "with", "the", "proband", "relatives", "and", "their", "consent", "for", "release", "of", "medical", "records", "and", "use", "of", "the", "pathological", "tissue", "blocks", "still", "available." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 13, 13, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
As screening method for HNPCC we searched for MSI in the proband's primary tumor and metastasis tissue blocks. The absence of proband's non-tumor DNA for MSI testing was overcome studying the alleles carried by his progenitors. Once the MSI was established, a second blood sample was obtained from the proband's mother (obligate carrier but at the moment of the study still unaffected) to full mutation analysis of the hMSH2 and hMLH1 genes by direct sequencing. After identifying the family mutation, we searched it in both proband's sisters sisters ) of a male who died of poorly differentiated colorectal adenocarcinoma at age 23 contacted us for genetic counseling. A detailed family and medical history was obtained through interview with the proband relatives and their consent for release of medical records and use of the pathological tissue blocks still available.
2275286-04-Results-p02
[ "Clinical", "features", "of", "patients", "in", "MSI", "group", "with", "MMR", "gene", "mutations" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Clinical features of patients in MSI group with MMR gene mutations
2386495-02-Background-p01
[ "Different", "genotype-phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[26-28].", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene.", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "10–15%", " ", "of", "the", "FAP", "patients", "could", "have", "a", "reduced", "or", "absent", "APC", "expression", "[18].", "The", "cause", "of", "the", "reduced", "expression", "is", "not", "known", "but", "the", "patients", "show", "a", "similar", "phenotype", "to", "those", "with", "an", "identified", "truncating", "APC", "mutation", "[19-21].", "It", "has", "been", "shown", "that", "a", "decrease", "of", "approximately", "50%", "of", "the", "expression", "of", "an", "allele", "can", "result", "in", "a", "predisposition", "to", "FAP", "[20].", "Germline", "APC-mutation", "mosaicism", "in", "FAP", "patients", "has", "been", "reported", "[22-25]", "but", "is", "not", "generally", "included", "in", "the", "mutation", "screening", "procedure", "provided", "by", "most", "labs", "owing", "to", "the", "technical", "difficulties", "encountered", "with", "these", "analyses." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 18, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses.
2386495-05-Discussion-p03
[ "Two", "novel", "germline", "APC", "mutations", "that", "introduce", "different", "cryptic", "splice", "sites", "are", "characterized", "in", "this", "study.", "Both", "mutations", "result", "in", "the", "aberrant", "splicing", "of", "APC", "exons", "7", "and", "8", "and", "prematurely", "truncated", "APC", "protein,", "and", "both", "are", "defined", "as", "pathogenic.", "The", "aberrant", "splicing", "identified", "in", "patient", "C496", "(", "c.835-7T", ">", "G", "patients", " ", "uses", "mainly", "PCR-based", "methods", "for", "analysis", "of", "the", "APC", "gene", "in", "DNA", "from", "isolated", "blood", "samples.", "Therefore,", "the", "chances", "of", "detecting", "pathogenic", "low-frequency", "APC", "mutations", "that", "are", "present", "only", "in", "a", "small", "fraction", "of", "the", "peripheral", "blood", "cells", "or", "only", "in", "the", "colon", "are", "poor.", "Approximately", "25%", "of", "neurofibromatosis", "type", "2", "(NF2)", "patients", "have", "been", "shown", "to", "be", "cases", "of", "mosaicism", "[44].", "When", "investigating", "NF2", "mutational", "mosaicism,", "the", "search", "for", "constitutional", "mutations", "is", "preferably", "carried", "out", "initially", "in", "tumor", "cells.", "Detected", "mutations", "could", "subsequently", "be", "verified", "in", "blood", "leukocyte", "samples.", "However,", "this", "approach", "would", "not", "be", "applicable", "for", "FAP", "mosaisicm", "as", "somatic", "APC", "mutations", "are", "frequently", "found", "in", "tumors." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Two novel germline APC mutations that introduce different cryptic splice sites are characterized in this study. Both mutations result in the aberrant splicing of APC exons 7 and 8 and prematurely truncated APC protein, and both are defined as pathogenic. The aberrant splicing identified in patient C496 ( c.835-7T > G patients uses mainly PCR-based methods for analysis of the APC gene in DNA from isolated blood samples. Therefore, the chances of detecting pathogenic low-frequency APC mutations that are present only in a small fraction of the peripheral blood cells or only in the colon are poor. Approximately 25% of neurofibromatosis type 2 (NF2) patients have been shown to be cases of mosaicism [44]. When investigating NF2 mutational mosaicism, the search for constitutional mutations is preferably carried out initially in tumor cells. Detected mutations could subsequently be verified in blood leukocyte samples. However, this approach would not be applicable for FAP mosaisicm as somatic APC mutations are frequently found in tumors.
1334229-03-Methods-p01
[ "DNA", "isolation" ]
[ 0, 0 ]
DNA isolation
3034663-03-Methods-p01
[ "We", "genotyped", "the", "p.Lys618Ala", "variant", "in", "MLH1", "in", "1034", "individuals", "(373", "sporadic", "CRC", "patients,", "250", "index", "subjects", "from", "families", "suspected", "of", "having", "LS", "[revised", "Bethesda", "Guidelines]", "and", "411", "controls).", "The", "controls", "were", "selected", "from", "the", "same", "hospitals,", "had", "no", "personal", "histories", "of", "cancer", "and", "had", "diagnoses", "unrelated", "to", "the", "variables", "of", "interest.", "They", "were", "matched", "for", "age,", "gender", "and", "race/ethnicity", "with", "the", "sporadic", "CRC", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We genotyped the p.Lys618Ala variant in MLH1 in 1034 individuals (373 sporadic CRC patients, 250 index subjects from families suspected of having LS [revised Bethesda Guidelines] and 411 controls). The controls were selected from the same hospitals, had no personal histories of cancer and had diagnoses unrelated to the variables of interest. They were matched for age, gender and race/ethnicity with the sporadic CRC patients.
2386495-04-Results-p02
[ "A", "case", "of", "APC", "mosaicism" ]
[ 0, 0, 0, 0, 0 ]
A case of APC mosaicism
1334229-05-Discussion-p02
[ "The", "K-ras", "mutation", "frequency", "of", "37%", "is", "in", "accordance", "with", "reported", "frequencies", "of", "30", "to", "60%", "[33-43].", "The", "frequency", "of", "37%", "of", "truncating", "mutations", "in", "the", "mutation", "cluster", "region", "of", "APC", "in", "this", "study,", "however,", "seems", "low", "in", "comparison", "to", "the", "general", "assumption", "that", "most", "colorectal", "tumours", "harbour", "a", "mutation", "in", "the", "APC", "gene.", "When", "only", "reports", "from", "studies", "on", "sporadic", "rather", "than", "familial", "colorectal", "cancer", "or", "colorectal", "cancer", "cell", "lines", "are", "considered,", "the", "mutation", "frequencies", "are", "lower", "and", "vary", "between", "30", "and", "70%", "[17,44-49],", "and", "a", "population-based", "case-control", "study", "in", "the", "Netherlands", "reported", "a", "32%", "mutation", "frequency", "[50]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The K-ras mutation frequency of 37% is in accordance with reported frequencies of 30 to 60% [33-43]. The frequency of 37% of truncating mutations in the mutation cluster region of APC in this study, however, seems low in comparison to the general assumption that most colorectal tumours harbour a mutation in the APC gene. When only reports from studies on sporadic rather than familial colorectal cancer or colorectal cancer cell lines are considered, the mutation frequencies are lower and vary between 30 and 70% [17,44-49], and a population-based case-control study in the Netherlands reported a 32% mutation frequency [50].
1557864-05-Discussion-p02
[ "Since", "ovarian", "cancer", "is", "a", "heterogeneous", "disease", "characterized", "by", "various", "histological", "types", "which", "may", "have", "different", "MSI", "frequencies,", "the", "number", "of", "specimens", "analyzed", "is", "very", "important", "in", "characterizing", "a", "feature", "that", "may", "be", "uncommon", "such", "as", "MSI.", "We", "therefore,", "made", "a", "summary", "of", "20", "studies", "totaling", "1315", "ovarian", "carcinomas,", "to", "compare", "the", "findings", "of", "these", "studies", "with", "our", "results", "(Table", "2).", "The", "MSI", "frequencies", "determined", "in", "these", "studies", "ranged", "from", "0%", "to", "39%.", "Overall,", "MSI", "was", "detected", "in", "165", "of", "the", "1315", "ovarian", "carcinomas", "tested,", "suggesting", "an", "overall", "incidence", "of", "13%", "tumors", "MLH1", "promoter", "methylation", "MLH1", "promoter", "methylation", "carcinomas", "carcinomas", "carcinomas", "carcinomas", " ", "to", "determine", "the", "frequency", "of", "MMR", "inactivation", "in", "ovarian", "cancer", "in", "vivo.", "Seven", "of", "the", "75", "ovarian", "carcinomas", "showed", "MLH1", "promoter", "methylation.", "We", "confirmed", "whether", "the", "observed", "MLH1", "promoter", "methylation", "results", "in", "the", "inactivation", "of", "the", "gene", "by", "determining", "the", "MLH1", "mRNA", "expression", "with", "quantitative", "RT-PCR.", "The", "six", "tumors", "with", "low", "level", "MLH1", "promoter", "methylation", "appeared", "to", "express", "MLH1", "at", "mRNA", "levels", "similar", "to", "that", "of", "the", "unmethylated", "tumors.", "Thus", "a", "low", "level", "of", "methylation", "does", "not", "result", "in", "an", "altered", "expression", "of", "the", "MLH1", "gene.", "In", "contrast,", "the", "abundant", "methylation", "seen", "in", "the", "remaining", "carcinoma", "was", "associated", "with", "the", "lowest", "MLH1", "mRNA", "expression", "level", "of", "all", "50", "ovarian", "carcinomas", "tested.", "However,", "none", "of", "the", "ovarian", "carcinomas", "showed", "MSI", "for", "BAT25,", "BAT26", "and", "for", "BAT40", "or", "D2S123", "which", "suggests", "a", "frequency", "of", "MMR", "inactivation", "of", "0%.", "The", "low", "MLH1", "mRNA", "expression", "seen", "in", "the", "abundant", "methylated", "carcinoma", "might", "be", "sufficient", "enough", "for", "a", "functional", "MMR", "which", "results", "in", "the", "observed", "absence", "of", "MSI." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 1, 7, 8, 8, 7, 8, 8, 9, 1, 9, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Since ovarian cancer is a heterogeneous disease characterized by various histological types which may have different MSI frequencies, the number of specimens analyzed is very important in characterizing a feature that may be uncommon such as MSI. We therefore, made a summary of 20 studies totaling 1315 ovarian carcinomas, to compare the findings of these studies with our results (Table 2). The MSI frequencies determined in these studies ranged from 0% to 39%. Overall, MSI was detected in 165 of the 1315 ovarian carcinomas tested, suggesting an overall incidence of 13% tumors MLH1 promoter methylation MLH1 promoter methylation carcinomas carcinomas carcinomas carcinomas to determine the frequency of MMR inactivation in ovarian cancer in vivo. Seven of the 75 ovarian carcinomas showed MLH1 promoter methylation. We confirmed whether the observed MLH1 promoter methylation results in the inactivation of the gene by determining the MLH1 mRNA expression with quantitative RT-PCR. The six tumors with low level MLH1 promoter methylation appeared to express MLH1 at mRNA levels similar to that of the unmethylated tumors. Thus a low level of methylation does not result in an altered expression of the MLH1 gene. In contrast, the abundant methylation seen in the remaining carcinoma was associated with the lowest MLH1 mRNA expression level of all 50 ovarian carcinomas tested. However, none of the ovarian carcinomas showed MSI for BAT25, BAT26 and for BAT40 or D2S123 which suggests a frequency of MMR inactivation of 0%. The low MLH1 mRNA expression seen in the abundant methylated carcinoma might be sufficient enough for a functional MMR which results in the observed absence of MSI.
1334229-04-Results-p01
[ "Of", "656", "tumours", "for", "which", "the", "other", "molecular", "alterations,", "i.e.", "mutations", "in", "the", "APC", "and", "K-ras", "genes", "and", "hMLH1", "expression,", "were", "all", "successfully", "and", "completely", "analysed,", "103", "colorectal", "tumours", "did", "not", "harbour", "a", "truncating", "or", "missense", "APC", "mutation,", "an", "activating", "K-ras", "mutation", "or", "showed", "lack", "of", "hMLH1", "expression,", "as", "depicted", "in", "figure", "1.", "Truncating", "as", "well", "as", "missense", "APC", "mutations", "and", "activating", "K-ras", "mutations", "were", "relatively", "common.", "Truncating", "APC", "mutations", "alone", "and", "activating", "K-ras", "mutations", "in", "codons", "12", "and", "13", "only,", "occurred", "at", "similar", "frequencies", "(20%", "(130/656)", "and", "18%", "(121/656),", "respectively).", "A", "combination", "of", "a", "truncating", "mutation", "in", "APC", "and", "an", "activating", "mutation", "in", "K-ras", "occurred", "less", "often", "than", "the", "sole", "occurrences", "of", "mutations", "in", "both", "genes.", "However,", "as", "shown", "in", "table", "2,", "the", "simultaneous", "occurrence", "of", "mutations", "in", "both", "genes", "occurred", "more", "frequently", "than", "expected", "on", "the", "basis", "of", "chance", "alone.", "A", "χ2", "test", "for", "the", "occurrence", "of", "a", "truncating", "APC", "mutation", "and", "an", "activating", "K-ras", "mutation", "revealed", "that", "the", "occurrence", "of", "these", "mutations", "was", "not", "independent", "(χ2", "=", "8.7,", "P", "<", "0.001),", "but", "the", "correlation", "was", "weak", "(Cramérs", "V", "=", "0.138).", "Finally,", "although", "11", "tumours", "that", "harboured", "a", "mutation", "in", "the", "APC", "or", "K-ras", "gene", "also", "lacked", "hMLH1", "expression,", "hMLH1", "deficiency", "occurred", "more", "frequently", "in", "tumours", "Three", "of", "these", "five", " ", "tumours", "showed", "hMLH1", "deficiency.", "Two", "colorectal", "cancer", "patients", "harboured", "a", "mutation", "in", "the", "CTNNB1", "gene,", "that", "did", "not", "occur", "at", "the", "Ser/Thr", "phosphorylation", "sites,", "but", "would", "result", "in", "an", "amino", "acid", "alteration", "at", "codons", "22", "and", "29,", "the", "effects", "of", "which", "are", "unknown.", "Because", "of", "the", "very", "low", "frequency", "of", "tumours", "harbouring", "a", "CTNNB1", "mutation,", "these", "mutations", "were", "not", "included", "in", "further", "analyses.", "In", "addition,", "mutation", "analysis", "of", "remaining", "samples", "was", "abandoned,", "since", "this", "was", "deemed", "irrelevant", "as", "these", "harboured", "truncating", "APC", "mutations", "and", "are", "considered", "to", "be", "unlikely", "to", "also", "have", "CTNNB1", "mutations", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 11, 12, 12, 12, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Of 656 tumours for which the other molecular alterations, i.e. mutations in the APC and K-ras genes and hMLH1 expression, were all successfully and completely analysed, 103 colorectal tumours did not harbour a truncating or missense APC mutation, an activating K-ras mutation or showed lack of hMLH1 expression, as depicted in figure 1. Truncating as well as missense APC mutations and activating K-ras mutations were relatively common. Truncating APC mutations alone and activating K-ras mutations in codons 12 and 13 only, occurred at similar frequencies (20% (130/656) and 18% (121/656), respectively). A combination of a truncating mutation in APC and an activating mutation in K-ras occurred less often than the sole occurrences of mutations in both genes. However, as shown in table 2, the simultaneous occurrence of mutations in both genes occurred more frequently than expected on the basis of chance alone. A χ2 test for the occurrence of a truncating APC mutation and an activating K-ras mutation revealed that the occurrence of these mutations was not independent (χ2 = 8.7, P < 0.001), but the correlation was weak (Cramérs V = 0.138). Finally, although 11 tumours that harboured a mutation in the APC or K-ras gene also lacked hMLH1 expression, hMLH1 deficiency occurred more frequently in tumours Three of these five tumours showed hMLH1 deficiency. Two colorectal cancer patients harboured a mutation in the CTNNB1 gene, that did not occur at the Ser/Thr phosphorylation sites, but would result in an amino acid alteration at codons 22 and 29, the effects of which are unknown. Because of the very low frequency of tumours harbouring a CTNNB1 mutation, these mutations were not included in further analyses. In addition, mutation analysis of remaining samples was abandoned, since this was deemed irrelevant as these harboured truncating APC mutations and are considered to be unlikely to also have CTNNB1 mutations [7].
1619718-05-Discussion-p01
[ "Adenomas" ]
[ 0 ]
Adenomas
1619718-05-Discussion-p03
[ "Colorectal", "polyps", "have", "traditionally", "been", "classified", "into", "distinct", "histogenetic", "types", "that", "may", "progress", "to", "CRC", "through", "independent", "pathways", "of", "colorectal", "tumorigenesis", "(Table", "2).", "However,", "in", "addition", "to", "the", "two", "‘classical’", "pathways", "to", "CRC", "shown", "in", "Table", "2,", "there", "may", "be", "‘fusion’", "pathways", "that", "combine", "mechanisms", "associated", "with", "both", "adenomas", "and", "serrated", "polyps.", "This", "would", "explain", "why", "many", "CRCs", "display", "phenotypes", "associated", "with", "serrated", "polyps", "as", "well", "as", "adenomas.44", "Three", "possible", "examples", "of", "such", "fusion", "pathways", "are", "shown", "in", "Table", "3.", "It", "is", "difficult", "to", "observe", "directly", "the", "actual", "point", "of", "transition", "from", "benign", "to", "malignant", "colorectal", "lesions.", "Once", "the", "key", "rate-limiting", "step", "is", "achieved", "it", "is", "likely", "that", "the", "transition", "to", "cancer", "occurs", "rapidly", "and", "the", "precursor", "lesion", "is", "then", "overtaken", "by", "the", "malignancy.", "Changes", "leading", "to", "inactivation", "of", "either", "TP535", "or", "the", "DNA", "mismatch", "repair", "gene", "MLH113", "are", "likely", "to", "be", "two", "such", "rate-limiting", "mechanisms.", "Only", "a", "single", "instance", "of", "loss", "of", "expression", "of", "MLH1", "was", "observed", "in", "the", "present", "series", "of", "polyps", "and", "the", "adenoma", "in", "question", "was", "inferred", "to", "be", "from", "a", "patient", " ", "with", "Lynch", "syndrome.24" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0 ]
Colorectal polyps have traditionally been classified into distinct histogenetic types that may progress to CRC through independent pathways of colorectal tumorigenesis (Table 2). However, in addition to the two ‘classical’ pathways to CRC shown in Table 2, there may be ‘fusion’ pathways that combine mechanisms associated with both adenomas and serrated polyps. This would explain why many CRCs display phenotypes associated with serrated polyps as well as adenomas.44 Three possible examples of such fusion pathways are shown in Table 3. It is difficult to observe directly the actual point of transition from benign to malignant colorectal lesions. Once the key rate-limiting step is achieved it is likely that the transition to cancer occurs rapidly and the precursor lesion is then overtaken by the malignancy. Changes leading to inactivation of either TP535 or the DNA mismatch repair gene MLH113 are likely to be two such rate-limiting mechanisms. Only a single instance of loss of expression of MLH1 was observed in the present series of polyps and the adenoma in question was inferred to be from a patient with Lynch syndrome.24
1334229-02-Background-p01
[ "Activation", "of", "the", "Wnt", "pathway", "plays", "a", "central", "role", "in", "the", "aetiology", "of", "most", "colorectal", "cancers", "and", "is", "often", "the", "result", "of", "mutations", "in", "the", "N-terminal", "domain", "of", "the", "APC", "gene,", "that", "lead", "to", "partial", "or", "complete", "loss", "of", "this", "region", "and", "thereby", "to", "loss", "of", "the", "β-catenin", "regulating", "function", "[5,6].", "Conversely,", "in", "tumours", "lacking", "these", "APC", "mutations", "[7],", "activating", "missense", "mutations", "at", "one", "of", "the", "phosphorylation", "sites", "at", "codons", "31,", "33,", "37", "and", "45", "of", "exon", "3", "of", "the", "CTNNB1", "gene", "(encoding", "the", "β-catenin", "protein)", "can", "render", "it", "stable", "as", "it", "can", "no", "longer", "be", "tagged", "for", "cellular", "degradation.", "Activation", "of", "the", "Ras", "pathway", "in", "cancer", "is", "marked", "by", "the", "loss", "of", "the", "intrinsic", "GTPase", "activity", "of", "the", "Ras", "protein,", "which", "can", "be", "ascribed", "to", "missense", "mutations", "in", "codons", "12", "and", "13", "of", "exon", "1,", "which", "are", "responsible", "for", "90%", "activating", "mutations", "in", "the", "of", "the", "K-ras", "gene", "[8]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Activation of the Wnt pathway plays a central role in the aetiology of most colorectal cancers and is often the result of mutations in the N-terminal domain of the APC gene, that lead to partial or complete loss of this region and thereby to loss of the β-catenin regulating function [5,6]. Conversely, in tumours lacking these APC mutations [7], activating missense mutations at one of the phosphorylation sites at codons 31, 33, 37 and 45 of exon 3 of the CTNNB1 gene (encoding the β-catenin protein) can render it stable as it can no longer be tagged for cellular degradation. Activation of the Ras pathway in cancer is marked by the loss of the intrinsic GTPase activity of the Ras protein, which can be ascribed to missense mutations in codons 12 and 13 of exon 1, which are responsible for 90% activating mutations in the of the K-ras gene [8].
1619718-05-Discussion-p01
[ "The", "adenomas", "in", "this", "study", "were", "grouped", "as", "TAs", "<", " ", "10", "mm,", "TAs", ">", " ", "10", "mm", "and", "TVAs/VAs.", "Overall,", "KRAS", "mutation", "occurred", "in", "26.5%", "of", "adenomas", "while", "BRAF", "mutation", "was", "detected", "in", "only", "4.8%.", "Three", "of", "the", "four", "BRAF", "mutations", "occurred", "in", "adenomas", "that", "also", "had", "KRAS", "mutation.", "It", "is", "well", "established", "that", "BRAF", "and", "KRAS", "mutation", "rarely", "occur", "in", "the", "same", "colorectal", "neoplasm.12,16,30", "Furthermore,", "BRAF", "mutations", "are", "much", "more", "typical", "of", "serrated", "polyps", "than", "adenomas.14,31", "The", "assay", "for", "BRAF", "mutation", "used", "in", "this", "study", "was", "highly", "sensitive", "and", "it", "is", "possible", "that", "the", "mutation", "was", "being", "identified", "in", "normal", "mucosa", "included", "with", "the", "polyp.", "KRAS", "mutation", "may", "occur", "within", "apparently", "normal", "colorectal", "mucosa", "and", "the", "same", "could", "apply", "to", "BRAF.32", "Therefore,", "the", "finding", "of", "BRAF", "mutation", "in", "a", "small", "subset", "of", "adenomas", "could", "be", "spurious", "and", "the", "true", "incidence", "of", "BRAF", "mutation", "in", "colorectal", "adenomas", "could", "be", "lower", "than", "4.8%.", "BRAF", "mutation", "frequencies", "of", "0%14", "and", "3%31", "have", "been", "reported", "in", "other", "series", "of", "colorectal", "adenomas." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The adenomas in this study were grouped as TAs <   10 mm, TAs >   10 mm and TVAs/VAs. Overall, KRAS mutation occurred in 26.5% of adenomas while BRAF mutation was detected in only 4.8%. Three of the four BRAF mutations occurred in adenomas that also had KRAS mutation. It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.12,16,30 Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.14,31 The assay for BRAF mutation used in this study was highly sensitive and it is possible that the mutation was being identified in normal mucosa included with the polyp. KRAS mutation may occur within apparently normal colorectal mucosa and the same could apply to BRAF.32 Therefore, the finding of BRAF mutation in a small subset of adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
2386495-04-Results-p02
[ "Mutation", "at", "the", "far", "5'end" ]
[ 0, 0, 0, 0, 0 ]
Mutation at the far 5'end
2386495-04-Results-p02
[ "Three", "patients", "(C107,", "C257,", "and", "C505),", "negative", "for", "mutations", "in", "APC,", "were", "reported", "as", "de", "novo", "cases", "with", "no", "known", "family", "history", "of", "FAP.", "These", "patients", "where", "all", "screened", "for", "APC", "mutations", "present", "as", "low-frequency", "alleles", "using", "SSCP/HD.", "We", "did", "not", "detect", "any", "signs", "of", "low-frequency", "mutations", "in", "patients", "C257", "and", "C505.", "However,", "in", "patient", "C107,", "aberrant", "bands,", "possibly", "originating", "from", "formation", "of", "heteroduplexes,", "was", "detected", "by", "SSCP/HD", "in", "a", "very", "low", "fraction", "of", "her", "blood", "lymphocytes.", "The", "c.2700_2701delTC", "mutation,", "which", "results", "in", "frame", "shift", "at", "codon", "900", "APC", " ", "gene", "(Figure", "1C).", "Three", "of", "these", "deletions", "have", "not,", "to", "the", "best", "of", "the", "authors'", "knowledge,", "been", "described", "earlier.", "The", "deletion", "encompassing", "APC", "exon", "4", "in", "patient", "3765,", "c.423-1662_531+1825del3595,", "was", "detected", "by", "RNA-based", "PTT", "with", "subsequent", "cDNA", "sequencing", "and", "verified", "by", "long-range", "PCR", "on", "genomic", "DNA.", "We", "could", "not", "detect", "this", "deletion", "with", "MLPA", "even", "though", "a", "probe", "for", "exon", "4", "is", "included", "in", "the", "MLPA", "kit", "(see", "the", "discussion).", "Detection", "of", "the", "large", "deletion", "in", "patient", "C591,", "encompassing", "APC", "exons", "13", "through", "the", "5'", "part", "of", "exon", "15,", "was", "carried", "out", "with", "MLPA.", "The", "deletion", "in", "patient", "2136", "was", "identified", "by", "PTT", "and", "subsequent", "DNA", "sequencing." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 6, 6, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three patients (C107, C257, and C505), negative for mutations in APC, were reported as de novo cases with no known family history of FAP. These patients where all screened for APC mutations present as low-frequency alleles using SSCP/HD. We did not detect any signs of low-frequency mutations in patients C257 and C505. However, in patient C107, aberrant bands, possibly originating from formation of heteroduplexes, was detected by SSCP/HD in a very low fraction of her blood lymphocytes. The c.2700_2701delTC mutation, which results in frame shift at codon 900 APC gene (Figure 1C). Three of these deletions have not, to the best of the authors' knowledge, been described earlier. The deletion encompassing APC exon 4 in patient 3765, c.423-1662_531+1825del3595, was detected by RNA-based PTT with subsequent cDNA sequencing and verified by long-range PCR on genomic DNA. We could not detect this deletion with MLPA even though a probe for exon 4 is included in the MLPA kit (see the discussion). Detection of the large deletion in patient C591, encompassing APC exons 13 through the 5' part of exon 15, was carried out with MLPA. The deletion in patient 2136 was identified by PTT and subsequent DNA sequencing.
1619718-04-Results-p01
[ "SSAs", "were", "more", "likely", "to", "have", "BRAF", "mutation", "(81%)", "than", "either", "SAs", "(33%)", "(P", "<", "0.001)", "or", "MPs", "(40%)", "(P", "<", "0.02).", "KRAS", "mutation", "was", "infrequent", "among", "both", "SSAs", "(3%)", "and", "HPs", "(4%)", "(Table", "1).", "Patient", "age,", "gender", "and", "anatomical", "location", "were", "not", "predictors", "of", "BRAF", "mutation", "in", "either", "SSAs", "or", "HPs.", "The", "mean", "age", "of", "subjects", " ", "with", "SSAs", "(64", "years)", "differed", "from", "that", "of", "subjects", "SSAs", "MGMT", " ", "loss", "differs", "across", "the", "seven", "classes", "of", "polyp", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
SSAs were more likely to have BRAF mutation (81%) than either SAs (33%) (P < 0.001) or MPs (40%) (P < 0.02). KRAS mutation was infrequent among both SSAs (3%) and HPs (4%) (Table 1). Patient age, gender and anatomical location were not predictors of BRAF mutation in either SSAs or HPs. The mean age of subjects with SSAs (64 years) differed from that of subjects SSAs MGMT loss differs across the seven classes of polyp (P < 0.001).
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "gender", "in", "43", "cases,", "infiltrating", "lymphocytes", "in", "55", "cases,", "nodal", "involvement", "in", "77", "cases,", "tumor", "site", "in", "56", "cases,", "grade", "in", "106", "cases", "and", "mucinous", "appearance", "in", "89", "cases." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 cases and mucinous appearance in 89 cases.
2275286-04-Results-p02
[ "Clinical", "features", "of", "patients", "in", "MSI", "group", "with", "MMR", "gene", "mutations" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Clinical features of patients in MSI group with MMR gene mutations
2275286-04-Results-p02
[ "P", "=", "0.112" ]
[ 0, 0, 0 ]
P = 0.112
1334229-03-Methods-p01
[ "Tissue", "samples" ]
[ 0, 0 ]
Tissue samples
1619718-05-Discussion-p01
[ "In", "previous", "studies", "of", "KRAS", "in", "colorectal", "adenomas,", "mutation", "has", "been", "associated", "negatively", "with", "flat", "and", "depressed", "TAs", "and", "positively", "with", "polypoid", "appearance,", "increasing", "size,", "dysplasia,", "villous", "change", "and", "synchronous", "colorectal", "cancer.6,33–35", "In", "by", "far", "the", "largest", "study,", "which", "included", "738", "adenomas", "obtained", "from", "639", "participants", "serrated", "and/or", "villous", "architecture", "hyperplastic", "and", "dysplastic", ")", "and", "a", "serrated", "and/or", "villous", "architecture." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 19, 20, 20, 20, 19, 20, 20, 0, 0, 0, 0, 0, 0, 0 ]
In previous studies of KRAS in colorectal adenomas, mutation has been associated negatively with flat and depressed TAs and positively with polypoid appearance, increasing size, dysplasia, villous change and synchronous colorectal cancer.6,33–35 In by far the largest study, which included 738 adenomas obtained from 639 participants serrated and/or villous architecture hyperplastic and dysplastic ) and a serrated and/or villous architecture.
1334229-01-Abstract-p01
[ "Abstract" ]
[ 0 ]
Abstract
1373649-03-Methods-p02
[ "A", "second", "blood", "sample", "was", "obtained", "from", "the", "proband's", "mother", "and", "forwarded", "to", "the", "Department", "of", "Clinical", "Cancer", "Genetics", "(City", "of", "Hope", "Cancer", "Center,", "Duarte,", "California,", "USA)", "to", "full", "mutation", "analysis", "of", "the", "hMSH2", "tumor", "proband's", " ", "primary", "tumor", "(T')", "and", "its", "metastasis", "(T\")", "of", "those", "inherited", "from", "his", "biological", "mother", "(BM)", "and", "father", "(BF)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 1, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
A second blood sample was obtained from the proband's mother and forwarded to the Department of Clinical Cancer Genetics (City of Hope Cancer Center, Duarte, California, USA) to full mutation analysis of the hMSH2 tumor proband's primary tumor (T') and its metastasis (T") of those inherited from his biological mother (BM) and father (BF).
1334229-01-Abstract-p01
[ "Conclusion" ]
[ 0 ]
Conclusion
1619718-04-Results-p01
[ "Note:", "no", "result", "for", "KRAS", "in", "one", "sessile", "serrated", "adenoma", "(SSA)", "and", "one", "tubular", "adenoma", "(TA)", "or", "for", "BRAF", "in", "one", "TA.", "MGMT", "immunstaining", "not", "performed", "in", "15", "polyps", "(seven", "HPs,", "one", "SSA,", "one", "MP", "and", "six", "TAs)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Note: no result for KRAS in one sessile serrated adenoma (SSA) and one tubular adenoma (TA) or for BRAF in one TA. MGMT immunstaining not performed in 15 polyps (seven HPs, one SSA, one MP and six TAs).
2275286-03-Methods-p03
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1619718-04-Results-p03
[ "Aberrant", "expression", "of", "p53", "and", "correlation", "with", "MGMT", "loss" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Aberrant expression of p53 and correlation with MGMT loss
1619718-01-Abstract-p01
[ "Jass", "J", "R,", "Baker", "K,", "Zlobec", "I,", "Higuchi", "T,", "Barker", "M,", "Buchanan", "D", "&", "Young", "J", "(2006)", "Histopathology", "49,", "121–131" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Jass J R, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D & Young J (2006) Histopathology 49, 121–131
2386495-05-Discussion-p04
[ "The", "61", "different", "APC", "mutations", "listed", "in", "Additional", "file", "2", "were", "identified", "among", "81", "of", "the", "96", "families", "of", "the", "Swedish", "Polyposis", "Registry", "that", "were", "screened", "for", "APC", "mutations.", "Fifteen", "of", "the", "cases", "shown", "to", "be", "APC-", "mutation", " ", "negative", "where", "all", "subjected", "to", "mutational", "screening", "of", "the", "MUTYH", " ", "gene", "and", "six", "of", "them", " ", "were", "shown", "to", "carry", "biallelic", "MUTYH", "61", " ", "different", "APC", "mutations", "listed", "in", "Additional", "file", "2", "were", "identified", "among", "81", "of", "the", "96", "families", "of", "the", "Swedish", "Polyposis", "Registry", "that", "were", "screened", "for", "APC", "mutations.", "Fifteen", "of", "the", "cases", "shown", "to", "be", "APC-mutation", "negative", "where", "all", "subjected", "to", "mutational", "screening", "of", "the", "MUTYH", "gene", "and", "six", "of", "them", "were", "shown", "to", "carry", "biallelic", "MUTYH", "mutations", "germline", "epimutations", "family", " ", "did", "show", "positive", "linkage", "to", "the", "APC", "locus", "we", "decided", "to", "perform", "expression", "analyses", "and", "evidence", "of", "lowered", "APC", "expression", "was", "obtained", "by", "quantitative", "real-time", "PCR", "(Figure", "5A).", "The", "result", "was", "supported", "by", "the", "indication", "of", "a", "lower", "expression", "from", "the", "T-allele", "from", "analysis", "of", "the", "APC", "c.5465A", ">", "T", "polymorphism", "in", "the", "cDNA", "sequencing", "diagram", "of", "two", "affected", "family", "members", "(Figure", "5B).", "The", "search", "for", "mutations", "in", "the", "DNA", "sequence", "of", "the", "APC", "promoters", "has", "been", "initiated,", "but", "no", "pathogenic", "change", "has", "been", "detected", "to", "this", "date.", "The", "possibility", "of", "the", "pathogenic", "change", "being", "epigenetic", "will", "have", "to", "be", "investigated", "further.", "Hypermethylation", "of", "CpG", "sites", "in", "the", "promoter", "of", "APC", "has", "been", "reported", "as", "a", "means", "of", "gene", "silencing", "in", "colorectal", "tumors", "[46-49].", "To", "the", "best", "of", "the", "authors'", "knowledge", "no", "germ-line", "inactivation", "of", "APC", "caused", "by", "promoter", "hypermethylation", "has", "been", "reported.", "However,", "cases", "of", "pathogenic", "germline", "epimutations", "have", "been", "identified", "in", "the", "MLH1", "gene,", "which", "causes", "hereditary", "non-polyposis", "CRC", "[50,51]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 21, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 5, 6, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The 61 different APC mutations listed in Additional file 2 were identified among 81 of the 96 families of the Swedish Polyposis Registry that were screened for APC mutations. Fifteen of the cases shown to be APC- mutation negative where all subjected to mutational screening of the MUTYH gene and six of them were shown to carry biallelic MUTYH 61 different APC mutations listed in Additional file 2 were identified among 81 of the 96 families of the Swedish Polyposis Registry that were screened for APC mutations. Fifteen of the cases shown to be APC-mutation negative where all subjected to mutational screening of the MUTYH gene and six of them were shown to carry biallelic MUTYH mutations germline epimutations family did show positive linkage to the APC locus we decided to perform expression analyses and evidence of lowered APC expression was obtained by quantitative real-time PCR (Figure 5A). The result was supported by the indication of a lower expression from the T-allele from analysis of the APC c.5465A > T polymorphism in the cDNA sequencing diagram of two affected family members (Figure 5B). The search for mutations in the DNA sequence of the APC promoters has been initiated, but no pathogenic change has been detected to this date. The possibility of the pathogenic change being epigenetic will have to be investigated further. Hypermethylation of CpG sites in the promoter of APC has been reported as a means of gene silencing in colorectal tumors [46-49]. To the best of the authors' knowledge no germ-line inactivation of APC caused by promoter hypermethylation has been reported. However, cases of pathogenic germline epimutations have been identified in the MLH1 gene, which causes hereditary non-polyposis CRC [50,51].
3034663-04-Results-p01
[ "Results", "of", "genotyping", "for", "the", "p.Lys618Ala", "variant", "using", "the", "iPLEX", "Sequenom", "(A)", "and", "sequencing", "(B)", "methods." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Results of genotyping for the p.Lys618Ala variant using the iPLEX Sequenom (A) and sequencing (B) methods.
2386495-02-Background-p01
[ "Different", "genotype-phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[26-28].", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene.", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "of", "disease", "with", "early", "onset", "and", "profuse", "polyposis.", "The", "milder,", "attenuated", "form", "of", "disease", "(AFAP),", "characterized", "by", "less", "than", "100", "adenomas", "and", "later", "onset", "of", "adenomatosis", "and", "CRC,", "is", "often", "caused", "by", "mutations", "in", "the", "far", "5'", "and", "3'", "regions", "of", "the", "APC", "gene,", "as", "well", "as", "in", "the", "part", "excluded", "by", "alternative", "splicing", "of", "exon", "9", "[29]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29].
1619718-01-Abstract-p01
[ "Molecular", "alterations", "that", "are", "characteristic", "of", "the", "serrated", "pathway", "and", "adenoma–", "carcinoma", " ", "sequence", "can", "co-occur", "in", "a", "minority", "of", "advanced", "small", " ", "tubular", "adenomas", "(P", "<", "0.04).", "BRAF", "mutation", "was", "frequent", "in", "HPs", "(67%)", "and", "SSAs", "(81%),", "while", "KRAS", "mutation", "was", "infrequent", "(4%", "and", "3%,", "respectively).", "Of", "MPs", "and", "SAs,", "72%", "had", "either", "BRAF", "or", "KRAS", "mutation.", "Aberrant", "expression", "of", "p53", "was", "uncommon", "overall,", "but", "occurred", "more", "frequently", "in", "MPs", "and", "SAs", "(12%)", "than", "adenomas", "(1%)", "(P", "<", "0.04)", "and", "there", "was", "concordant", "loss", "of", "expression", "of", "MGMT." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 17, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Molecular alterations that are characteristic of the serrated pathway and adenoma– carcinoma sequence can co-occur in a minority of advanced small tubular adenomas (P < 0.04). BRAF mutation was frequent in HPs (67%) and SSAs (81%), while KRAS mutation was infrequent (4% and 3%, respectively). Of MPs and SAs, 72% had either BRAF or KRAS mutation. Aberrant expression of p53 was uncommon overall, but occurred more frequently in MPs and SAs (12%) than adenomas (1%) (P < 0.04) and there was concordant loss of expression of MGMT.
3034663-04-Results-p01
[ "Twenty-seven", "individuals", "were", "heterozygous", "for", "the", "p.Lys618Ala", "variant", "(Figure", "1);", "11", "were", "controls", "(11/411,", "2.68%),", "nine", "were", "CRC", "patients", "from", "the", "sporadic", "group", "(9/373,", "2.41%)", "and", "seven", "were", "CRC", "patients", "from", "the", "familial", "group", "(7/250,", "2.8%).", "None", "of", "the", "individuals", "was", "homozygous", "for", "the", "minor", "allele." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Twenty-seven individuals were heterozygous for the p.Lys618Ala variant (Figure 1); 11 were controls (11/411, 2.68%), nine were CRC patients from the sporadic group (9/373, 2.41%) and seven were CRC patients from the familial group (7/250, 2.8%). None of the individuals was homozygous for the minor allele.
3034663-03-Methods-p02
[ "Statistical", "analysis" ]
[ 0, 0 ]
Statistical analysis
2275286-01-Abstract-p01
[ "Abstract" ]
[ 0 ]
Abstract
1619718-01-Abstract-p01
[ "Advanced", "colorectal", "polyps", "with", "the", "molecular", "and", "morphological", "features", "of", "serrated", "polyps", "and", "adenomas:", "concept", "of", "a", "‘fusion’", "pathway", "to", "colorectal", "cancer" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer
1266026-01-Abstract-p01
[ "Ages", "at", "MSI+", "cancers", "were", "consistent", "with", "five", "or", "six", "oncogenic", "mutations", "for", "hereditary", "(HNPCC)", "cancers,", "and", "seven", "or", "eight", "mutations", "for", "its", "sporadic", "counterpart.", "Ages", "at", "cancer", "were", "consistent", "with", "seven", "mutations", "for", "sporadic", "MSI-", "cancers,", "and", "were", "similar", "(six", "to", "eight", "mutations)", "regardless", "of", "clinical", "cancer", "stage." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Ages at MSI+ cancers were consistent with five or six oncogenic mutations for hereditary (HNPCC) cancers, and seven or eight mutations for its sporadic counterpart. Ages at cancer were consistent with seven mutations for sporadic MSI- cancers, and were similar (six to eight mutations) regardless of clinical cancer stage.
1619718-03-Materials-and-methods-p02
[ "KRAS", "mutation", "analysis", "at", "codons", "12", "and", "13", "was", "performed", "using", "direct", "automated", "sequencing", "of", "a", "fragment", "containing", "codon", "12", "and", "13", "in", "exon", "1", "of", "the", "KRAS", "gene,", "amplified", "using", "a", "touchdown", "polymerase", "chain", "reaction", "(PCR)", "cycle", "and", "hotstart", "protocol.", "PCR", "products", "were", "initially", "purified", "and", "then", "directly", "sequenced", "using", "BigDye", "version", "3.1", "dye", "terminators", "and", "an", "ABI", "3100", "DNA", "fragment", "analyser.", "The", "sequence", "at", "codon", "12", "and", "13", "was", "determined", "using", "Mutation", "Surveyor", "(SoftGenetics,", "State", "College,", "PA,", "USA)", "software." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS mutation analysis at codons 12 and 13 was performed using direct automated sequencing of a fragment containing codon 12 and 13 in exon 1 of the KRAS gene, amplified using a touchdown polymerase chain reaction (PCR) cycle and hotstart protocol. PCR products were initially purified and then directly sequenced using BigDye version 3.1 dye terminators and an ABI 3100 DNA fragment analyser. The sequence at codon 12 and 13 was determined using Mutation Surveyor (SoftGenetics, State College, PA, USA) software.
1619718-04-Results-p01
[ "Mutation", "frequencies", "for", "both", "KRAS", "(P", "<", "0.0001)", "and", "BRAF", "(P", "<", "0.0001)", "are", "distributed", "differently", "across", "the", "seven", "classes", "of", "polyp", "(see", "Results", "for", "individual", "comparisons).", "Distribution", "of", "MGMT", "loss", "differs", "across", "the", "seven", "classes", "of", "polyp", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation frequencies for both KRAS (P < 0.0001) and BRAF (P < 0.0001) are distributed differently across the seven classes of polyp (see Results for individual comparisons). Distribution of MGMT loss differs across the seven classes of polyp (P < 0.001).
3034663-04-Results-p01
[ "Results", "of", "genotyping", "for", "the", "p.Lys618Ala", "variant", "using", "the", "iPLEX", "Sequenom", "(A)", "and", "sequencing", "(B)", "methods." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Results of genotyping for the p.Lys618Ala variant using the iPLEX Sequenom (A) and sequencing (B) methods.
1601966-03-Results-p04
[ "Up-regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "8q11.23-q21.13", "(patient", "counts", "with", "coordinate", "up-regulation).", "Grayscale", "plot", "of", "cross-comparison", "of", "up-regulation", "patterns", "across", "patients", "for", "gene", "pairs", "in", "a", "particular", "region.", "Both,", "horizontal", "and", "vertical", "axes", "comprise", "the", "same", "genes", "in", "chromosomal", "order.", "In", "each", "square", "total", "counts", "of", "patients", "with", "consistent", "up-regulation", "in", "two", "genes", "are", "coded", "by", "different", "shades", "of", "gray.", "Dark", "squared", "regions", "along", "the", "diagonal", "indicate", "coordinated", "regulation", "in", "patient", "subgroups.", "Note,", "that", "many", "more", "patients", "show", "up-regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "figure", "than", "down-regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "8.", "The", "left", "region", "of", "exceptionally", "strong", "up-regulation", "spans", "TCEA1,", "LYPLA1,", "MRPL15,", "the", "known", "tumor", "gene", "LYN,", "and", "PLAG1.", "Note", "that", "TOX", "and", "ANKTM1", "TOX", "PLAG1", ".", "Note", "that", "TOX", "and", "ANKTM1", "are", "down-regulated", "in", "approximately", "half", "of", "the", "tumor", "samples." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (patient counts with coordinate up-regulation). Grayscale plot of cross-comparison of up-regulation patterns across patients for gene pairs in a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total counts of patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along the diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show up-regulation as indicated by dark spots in this figure than down-regulation as indicated by dark spots in Figure 8. The left region of exceptionally strong up-regulation spans TCEA1, LYPLA1, MRPL15, the known tumor gene LYN, and PLAG1. Note that TOX and ANKTM1 TOX PLAG1 . Note that TOX and ANKTM1 are down-regulated in approximately half of the tumor samples.
1373649-04-Results-and-discussion-p01
[ "Protein", "sequence", "alignment", "for", "hMSH2", "and", "homologues.", "Human,", "Mouse,", "Rat,", "Chicken", "and", "Saccharomyces", "cerevisiae", "(the", "site", "of", "mutation", "is", "highlighted)", "protein", "sequence", "alignment.", "Evolutionary", "conservation", "may", "indicate", "the", "functional", "relevance", "of", "the", "aminoacid", "involved", "for", "the", "structure", "or", "functioning", "of", "the", "protein.", "*UniProtKB/Swiss-Prot" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Protein sequence alignment for hMSH2 and homologues. Human, Mouse, Rat, Chicken and Saccharomyces cerevisiae (the site of mutation is highlighted) protein sequence alignment. Evolutionary conservation may indicate the functional relevance of the aminoacid involved for the structure or functioning of the protein. *UniProtKB/Swiss-Prot
1334229-03-Methods-p03
[ "The", "χ2", "test", "and", "Cramérs", "V", "test", "were", "used", "to", "estimate", "the", "association", "of", "the", "co-occurrence", "of", "K-ras", "and", "APC", "gene", "mutations.", "Characteristics", "of", "patients", "(age", "at", "diagnosis,", "sex,", "family", "history", "of", "colorectal", "cancer)", "and", "tumours", "(tumour", "sub-localisation,", "Dukes'", "stage", "and", "tumour", "differentiation)", "were", "compared", "between", "patients", "with", "and", "without", "an", "activating", "K-ras", "or", "a", "truncating", "APC", "mutation", "as", "well", "as", "patients", "harbouring", "tumours", "with", "and", "without", "hMLH1", "expression,", "using", "Students", "T-test", "(age", "at", "diagnosis)", "and", "χ2", "tests", "(sex,", "family", "history", "of", "colorectal", "cancer,", "tumour", "sub-localisation,", "Dukes'", "stage", "and", "differentiation).", "Additionally,", "patient", "and", "tumour", "characteristics", "of", "tumours", "with", "an", "activating", "K-ras", "and/or", "a", "truncating", "APC", "K-ras", " ", "mutation", "status", "as", "well", "as", "hMLH1", "expression", "was", "complete", "were", "included." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The χ2 test and Cramérs V test were used to estimate the association of the co-occurrence of K-ras and APC gene mutations. Characteristics of patients (age at diagnosis, sex, family history of colorectal cancer) and tumours (tumour sub-localisation, Dukes' stage and tumour differentiation) were compared between patients with and without an activating K-ras or a truncating APC mutation as well as patients harbouring tumours with and without hMLH1 expression, using Students T-test (age at diagnosis) and χ2 tests (sex, family history of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation). Additionally, patient and tumour characteristics of tumours with an activating K-ras and/or a truncating APC K-ras mutation status as well as hMLH1 expression was complete were included.
3034663-03-Methods-p01
[ "No", "familial", "history", "of", "cancer", "was", "available", "from", "the", "control", "group.", "Patients", "diagnosed", "at", "an", "age", "over", "50", "years", "and", "not", "referred", "to", "Genetic", "Counselling", "Units", "were", "considered", "as", "sporadic", "CRC.", "Samples", "from", "sporadic", "CRC", "patients", "were", "obtained", "from", "the", "Elche", "University", "Hospital", "BioBank", "and", "the", "Castellon", "Provincial", "Hospital", "BioBank.", "Written", "consent", "to", "be", "included", "in", "the", "respective", "biobanks", "was", "obtained", "from", "each", "patient.", "CRC", "patients,", "as", "index", "subjects", "from", "families", "with", "suspicion", "of", "LS", "that", "attended", "Genetic", "Counselling", "at", "the", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals,", "were", "recruited.", "The", "study", "was", "approved", "by", "the", "Ethics", "Committee", "of", "the", "Elche", "University", "Hospital." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
No familial history of cancer was available from the control group. Patients diagnosed at an age over 50 years and not referred to Genetic Counselling Units were considered as sporadic CRC. Samples from sporadic CRC patients were obtained from the Elche University Hospital BioBank and the Castellon Provincial Hospital BioBank. Written consent to be included in the respective biobanks was obtained from each patient. CRC patients, as index subjects from families with suspicion of LS that attended Genetic Counselling at the Cancer Units of the Elche and La Fe Hospitals, were recruited. The study was approved by the Ethics Committee of the Elche University Hospital.
1266026-05-Discussion-p01
[ "An", "epigenetic", "mechanism", "may", "help", "explain", "why", "sporadic", "MSI+", "cancers", "require", "more", "than", "one", "additional", "somatic", "alteration", "relative", "to", "HNPCC", "cancers.", "Inactivation", "of", "the", "normal", "MMR", "allele", "occurs", "through", "mutation", "(usually", "LOH", "[15])", "in", "HNPCC", "whereas", "MMR", "loss", "in", "sporadic", "MSI+", "cancers", "is", "associated", "with", "MLH1", "promoter", "methylation", "[16,17].", "CpG", "islands", "may", "be", "\"protected\"", "from", "methylation", "because", "most", "are", "unmethylated", "at", "birth", "and", "usually", "remain", "unmethylated", "throughout", "life", "[18].", "Epigenetic", "MLH1", "inactivation", "may", "require", "at", "least", "two", "cis", "acting", "somatic", "alterations---loss", "of", "a", "mechanism", "that", "normally", "prevents", "methylation,", "followed", "by", "the", "accumulation", "of", "methylation", "at", "sufficient", "numbers", "of", "CpG", "sites", "to", "silence", "expression." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
An epigenetic mechanism may help explain why sporadic MSI+ cancers require more than one additional somatic alteration relative to HNPCC cancers. Inactivation of the normal MMR allele occurs through mutation (usually LOH [15]) in HNPCC whereas MMR loss in sporadic MSI+ cancers is associated with MLH1 promoter methylation [16,17]. CpG islands may be "protected" from methylation because most are unmethylated at birth and usually remain unmethylated throughout life [18]. Epigenetic MLH1 inactivation may require at least two cis acting somatic alterations---loss of a mechanism that normally prevents methylation, followed by the accumulation of methylation at sufficient numbers of CpG sites to silence expression.
2275286-01-Abstract-p01
[ "Thirty-four", "out", "of", "the", "146", "colorectal", "cancers", "(CRCs,", "23.2%)", "were", "MSI,", "including", "19", "MSI-H", "CRCs", "and", "15", "MSI-L", "CRCS.", "Negative", "staining", "for", "MSH2", "was", "found", "in", "8", "CRCs,", "negative", "staining", "for", "MSH6", "was", "found", "in", "6", "CRCs.", "One", "MSI-H", "CRC", "was", "negative", "for", "both", "MSH6", "and", "MSH2.", "Seventeen", "CRCs", "stained", "negatively", "for", "MLH1.", "MLH1", "promoter", "methylation", "was", "determined", "in", "34", "MSI", "CRCs.", "Hypermethylation", "of", "the", "MLH1", "promoter", "occurred", "in", "14", "(73.7%)", "out", "of", "19", "MSI-H", "CRCs", "and", "5", "(33.3%)", "out", "of", "15", "MSI-L", "CRCs.", "Among", "the", "34", "MSI", "carriers", " ", "and", "one", "MSS", "CRC", "with", "MLH1", "negative", "staining,", "8", "had", "a", "MMR", "gene", "germline", "mutation,", "which", "accounted", "for", "23.5%", "of", "all", "MSI", "colorectal", "cancers", "and", "5.5%", "of", "all", "the", "colorectal", "cancers.", "Five", "patients", "harbored", "MSH2", "germline", "mutations,", "and", "three", "patients", "harbored", "MSH6", "germline", "mutations.", "None", "of", "the", "patients", "Chinese", " ", "population", "with", "colorectal", "cancer" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 25, 0, 0, 0, 0, 0 ]
Thirty-four out of the 146 colorectal cancers (CRCs, 23.2%) were MSI, including 19 MSI-H CRCs and 15 MSI-L CRCS. Negative staining for MSH2 was found in 8 CRCs, negative staining for MSH6 was found in 6 CRCs. One MSI-H CRC was negative for both MSH6 and MSH2. Seventeen CRCs stained negatively for MLH1. MLH1 promoter methylation was determined in 34 MSI CRCs. Hypermethylation of the MLH1 promoter occurred in 14 (73.7%) out of 19 MSI-H CRCs and 5 (33.3%) out of 15 MSI-L CRCs. Among the 34 MSI carriers and one MSS CRC with MLH1 negative staining, 8 had a MMR gene germline mutation, which accounted for 23.5% of all MSI colorectal cancers and 5.5% of all the colorectal cancers. Five patients harbored MSH2 germline mutations, and three patients harbored MSH6 germline mutations. None of the patients Chinese population with colorectal cancer
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "MSI", "status", "in", "40", "cases,", "methylation", "status", "in", "83", "cases,", "KRAS", "mutation", "in", "26", "cases", "and", "TP53", "mutation", "in", "26", "cases" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for MSI status in 40 cases, methylation status in 83 cases, KRAS mutation in 26 cases and TP53 mutation in 26 cases
1266026-01-Abstract-p01
[ "Abstract" ]
[ 0 ]
Abstract
2275286-04-Results-p02
[ "The", "clinical", "features", "of", "MSI", "patients", "with", "MMR", "gene", "mutations", "are", "shown", "in", "Table", "5.", "Mean", "age", "was", "58.8", "years", "(range:", "34–78).", "Six", "were", "female", "and", "2", "were", "male.", "Only", "one", "patient", "had", "right", "side", "colonic", "lesion", "and", "2", "had", "mucinous", "carcinoma.", "There", "were", "no", "patients", "in", "Dukes'", "A", "or", "with", "synchronous/metachronous", "disease.", "Only", "one", "patient", "fulfilled", "the", "Amsterdam", "Criteria", "(II)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The clinical features of MSI patients with MMR gene mutations are shown in Table 5. Mean age was 58.8 years (range: 34–78). Six were female and 2 were male. Only one patient had right side colonic lesion and 2 had mucinous carcinoma. There were no patients in Dukes' A or with synchronous/metachronous disease. Only one patient fulfilled the Amsterdam Criteria (II).
2275286-01-Abstract-p01
[ "Conclusion" ]
[ 0 ]
Conclusion
1334229-03-Methods-p02
[ "APC", "mutation", "analysis" ]
[ 0, 0, 0 ]
APC mutation analysis
2275286-03-Methods-p04
[]
[]
3034663-03-Methods-p01
[ "The", "median", "age", "of", "patients", "in", "the", "sporadic", "CRC", "group", "was", "70", "years", "(range,", "52-93", "years),", "47", "years", "(range,", "21-87", "years)", "for", "the", "familial", "group", "and", "71", "years", "(range,", "25-96", "years)", "for", "the", "controls.", "The", "sex", "distribution", "was", "58%", "men", "and", "42%", "women", "for", "the", "sporadic", "CRC", "group", "and", "53.3%", "men", "and", "46.7%", "women", "for", "the", "controls." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The median age of patients in the sporadic CRC group was 70 years (range, 52-93 years), 47 years (range, 21-87 years) for the familial group and 71 years (range, 25-96 years) for the controls. The sex distribution was 58% men and 42% women for the sporadic CRC group and 53.3% men and 46.7% women for the controls.
1334229-03-Methods-p01
[ "Incident", "cancer", "cases", "are", "identified", "by", "monitoring", "of", "the", "entire", "cohort", "for", "cancer", "occurrence", "through", "annual", "record", "linkage", "to", "the", "Netherlands", "Cancer", "Registry,", "i.e.", "nine", "regional", "cancer", "registries", "throughout", "the", "Netherlands,", "and", "to", "PALGA,", "a", "nationwide", "network", "and", "registry", "of", "histo-", "and", "cytopathology", "[30].", "Together,", "the", "NCR", "and", "PALGA", "provide", "a", "near", "100%", "coverage", "of", "the", "municipalities", "included", "in", "the", "NLCS.", "The", "first", "2.3", "years", "of", "follow", "up", "were", "excluded", "because", "of", "possible", "pre-clinical", "disease", "affecting", "exposure", "status", "and", "because", "of", "incomplete", "nationwide", "coverage", "of", "PALGA", "in", "some", "of", "the", "municipalities", "included", "in", "the", "NLCS", "in", "that", "period.", "From", "1989", "until", "1994,", "929", "incident", "cases", "with", "histologically", "confirmed", "colorectal", "cancer", "were", "identified", "within", "the", "cohort,", "of", "whom", "819", "could", "also", "be", "linked", "to", "a", "PALGA", "report", "of", "the", "lesion." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Incident cancer cases are identified by monitoring of the entire cohort for cancer occurrence through annual record linkage to the Netherlands Cancer Registry, i.e. nine regional cancer registries throughout the Netherlands, and to PALGA, a nationwide network and registry of histo- and cytopathology [30]. Together, the NCR and PALGA provide a near 100% coverage of the municipalities included in the NLCS. The first 2.3 years of follow up were excluded because of possible pre-clinical disease affecting exposure status and because of incomplete nationwide coverage of PALGA in some of the municipalities included in the NLCS in that period. From 1989 until 1994, 929 incident cases with histologically confirmed colorectal cancer were identified within the cohort, of whom 819 could also be linked to a PALGA report of the lesion.
2275286-04-Results-p02
[]
[]
1334229-01-Abstract-p01
[ "CTNNB1", "mutations", "seem", "to", "be", "of", "minor", "importance", "in", "sporadic", "colorectal", "cancer", "tumours", "carcinomas", " ", "from", "the", "Netherlands", "Cohort", "Study" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 9, 0, 0, 0, 0, 0, 0 ]
CTNNB1 mutations seem to be of minor importance in sporadic colorectal cancer tumours carcinomas from the Netherlands Cohort Study
3034663-03-Methods-p01
[ "Families", "carrying", "the", "p.Lys618Ala", "variant" ]
[ 0, 0, 0, 0, 0 ]
Families carrying the p.Lys618Ala variant
1373649-03-Methods-p01
[ "The", "early", "onset", "of", "the", "colon", "cancer", "in", "the", "proband", "and", "the", "study", "of", "the", "family's", "pedigree", "(fig.", "1),", "that", "fulfill", "the", "strict", "Amsterdam-1", "criteria,", "prompted", "genetic", "analysis", "with", "suspicion", "of", "HNPCC.", "They", "were", "informed", "about", "the", "risks,", "benefits", "and", "limitations", "of", "the", "study", "protocol." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The early onset of the colon cancer in the proband and the study of the family's pedigree (fig. 1), that fulfill the strict Amsterdam-1 criteria, prompted genetic analysis with suspicion of HNPCC. They were informed about the risks, benefits and limitations of the study protocol.
2275286-04-Results-p02
[ "The", "MSI", "state,", "mutation", "sites,", "and", "consequential", "changes", "in", "amino-acid", "sequences", "of", "MMR", "genes", "are", "summarized", "in", "Table", "4.", "In", "34", "MSI", "CRCs", "and", "one", "MSS", "CRC", "with", "MLH1", "negative", "staining,", "8", "had", "MMR", "gene", "germline", "mutations,", "accounting", "for", "22.9%", "of", "MSI", "colorectal", "cancers", "and", "5.5%", "of", "all", "colorectal", "cancers.", "Three", "patients", "had", "MSH6", "germline", "mutations", "and", "5", "had", "MSH2", "germline", "mutations;", "the", "clinical", "features", "of", "these", "patients", "are", "summarized", "in", "Table", "5.", "None", "of", "the", "patients", "had", "MLH1", "gene", "mutations.", "Seven", "patients", "in", "the", "MSI", "group", "had", "A/T", "heterozygosis", "in", "MSH6", "codon", "380", "of", "exon", "5,", "but", "it", "did", "not", "cause", "changes", "in", "the", "amino", "acid", "sequence.", "The", "germline", "mutations", "of", "the", "MSI-L", "and", "MSI-H", "CRCs", "are", "summarized", "in", "Table", "6.", "Six", "CRCs", "with", "mutations", "were", "MSI-H", "and", "two", "patients", "with", "mutations", "were", "MSI-L." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The MSI state, mutation sites, and consequential changes in amino-acid sequences of MMR genes are summarized in Table 4. In 34 MSI CRCs and one MSS CRC with MLH1 negative staining, 8 had MMR gene germline mutations, accounting for 22.9% of MSI colorectal cancers and 5.5% of all colorectal cancers. Three patients had MSH6 germline mutations and 5 had MSH2 germline mutations; the clinical features of these patients are summarized in Table 5. None of the patients had MLH1 gene mutations. Seven patients in the MSI group had A/T heterozygosis in MSH6 codon 380 of exon 5, but it did not cause changes in the amino acid sequence. The germline mutations of the MSI-L and MSI-H CRCs are summarized in Table 6. Six CRCs with mutations were MSI-H and two patients with mutations were MSI-L.
2275286-04-Results-p02
[ "P", "=", "0.112" ]
[ 0, 0, 0 ]
P = 0.112